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7Abbreviations
ACC Agkistrodon contortrix contortrix
APC Activated protein C
APTT Activated partial thromboplastin time
b1a2 Chimera containing C4BPb SCR-1 and C4BPa SCR-2 fused to a
modified tPA
Bmax Maximum binding
BSA Bovine serum albumin
C4BP C4b-binding protein
C4BPa C4BP a-chain
C4BPb C4BP b-chain
C4BPb+ C4BP containing a b-chain
CCP Complement control protein
CRP C-reactive protein
ELISA Enzyme linked immunosorbent assay
rC4BPa Recombinant C4BP containing only a-chains
SAP Serum amyloid P component
SCR Short consensus repeat, also designated CCP module
SCR-1 First amino-terminal SCR (derived from C4BPb)
SCR-2 Second amino-terminal SCR (derived from C4BPb or C4BPa)
SCR-3 Third amino-terminal SCR (derived from C4BPb)
SCR-1+2 SCR-1 + SCR-2
SCR-1+3 SCR-1 + SCR-3
SCR-2+3 SCR-2 + SCR-3
SDS-PAGE Sodium dodecyl sulphate polyacrylamide gel electrophoresis
SHBG Sex hormone bindi g globulin
TAFI Thrombin-activatable fibrinolysis inhibitor
TBS Tris-buffered saline
TFPI Tissue factor pathway inhibitor
tPA Tissue plasminogen activator
8Chapter 1
General introduction
9Haemostasis
All organs and tissues of higher organisms are provided with nutrients and oxygen through
the bloodstream. The bloodstream is an extensive vascular system that transports blood to all
the organs and tissues that comprise the organism. Blood contains red and white blood cells,
plasma and platelets. The red blood cells transport oxygen that is inhaled in the lungs to the
tissues, and carbon dioxide (a waste-product from the tissues) from the tissues to the lungs
where it can be exhaled. The white blood cells are responsible for the defence of the organism
against invading pathogens. Plasma is the liquid in which all other components are dissolved
and contains hormones and a great number of proteins. The bloodstream regulates body
temperature, oxygenation of tissues and cell function. Thus, maintenance of the vascular
system is of crucial importance to the organism. The vascular system is damaged upon tissue
rupture, and fatal blood loss would result if no mechanism was present to stop the bleeding.
To prevent bleeding, several mechanisms occur upon tissue rupture. First, the vessel contracts
at the site of injury. Vasoconstriction leads to immediate reduction of blood flow. Second,
platelets present in the bloodstream adhere to the ruptured vessel wall and form a plug. Third,
a network of fibrin fibers is deposited that stabilizes the platelet plug. Deposition of fibrin
fibers is regulated by an extensive system of proteins present in the blood that converts
soluble fibrinogen to a network of insoluble fibrin polymers. This system that finally leads to
fibrin formation upon activation is called the coagulation cascade. The mechanisms described
above finally result in the obstruction of the vascular system at the site of injury and thereby
further blood loss is prevented. Undesirable formation of such an obstruction inside the
vascular system (thrombosis) would lead to tissue damage or even death. Impaired status of
the vascular system or high sensitivity of platelets may lead to activation of platelets resulting
in obstruction of the vascular system due to platelet-induced coagulation (for instance in
atherosclerosis). On the other hand, when platelet activation and/or coagulation does not
occur when necessary or if a fibrin clot is degraded too rapidly, this will result in bleeding
complications. Therefore, it is evident that the haemostatic system must be well regulated.
Many inherited or acquired dysfunctions of the haemostatic system are known that may lead
to thrombotic or bleeding complications.
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The coagulation cascade
The coagulation system is a cascade system of proteolytic reactions (1,2). In each
proteolytic reaction, an inactive zymogen is converted to its active enzyme. The activated
enzyme then takes part in the subsequent proteolytic reaction of the coagulation cascade.
Surfaces of negatively charged phospholipids form a template to which many coagulation
factors can bind (3,4), combining the necessary components of the reactions and thereby
accelerating the coagulation cascade. Negatively charged phospholipid surfaces contain
phosphatidylserine and are provided by activated platelets that have adhered to the damaged
vessel wall (5,6). Coagulation factors that bind to negatively charged phospholipids are
factors VII, IX, X and prothrombin. In addition, two inhibitors of coagulation (protein C and
S) also have phospholipid-binding properties. Binding of these factors to phospholipids
involves calcium-dependent interactions between g-carboxyglutamic acid residues present in
the amino-terminal Gla-domains and the negatively charged phospholipids. Since g-
carboxylation of these glutamic acid residues is a vitamin K-dependent modification process,
these factors (coagulation factors VII, IX, X, prothrombin, protein C and S) are also called
vitamin K-dependent proteins (7,8). Other coagulation factors can have phospholipid binding
properties independent of Gla-domains, for example factors VIII and V (9). Negatively
charged phospholipids ensure that propagation of the coagulation process remains localized at
sites where these phospholipids are present. Due to the amplification characteristics of the
coagulation cascade, trace amounts of enzymes that are initially formed lead to massive
thrombin formation. Thrombin takes part in the final step of coagulation: the conversion of
soluble fibrinogen monomers to an insoluble network of fibrin polymers.
Initiation of coagulation
The vascular system is covered by a thin layer of cells called the endothelium. Endothelial
cells play an important role in regulating haemostasis by expressing proteins that regulate
activation of platelets and the coagulation cascade. Upon tissue rupture, the endothelium is
damaged and consequently, blood becomes exposed to subendothelial surfaces that are
normally covered by the endothelium. These subendothelial surfaces include collagen fibers,
von Willebrand factor and fibronectin, to which platelets adhere upon exposure. Platelets that
have adhered to the subendothelium become activated (5,6). A change in the phospholipid
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composition of the platelet membrane is one of the many events that occur upon platelet
activation. The change in phospholipid composition involves the transfer of negatively
charged phospholipids (phosphatidylserine) from the inner leaflet to the outer leaflet of the
platelet membranes. These negatively charged phospholipids form a template that accelerates
the coagulation cascade by binding of coagulation factors to these negatively charged
phospholipids (3,4).
In addition to collagen fibers, also tissue factor is present in the subendothelium. Tissue
factor is a transmembrane glycoprotein expressed on the surface of many cells except resting
endothelial cells. Tissue factor is an important trigger for the initiation of coagulation via the
so-called extrinsic pathway (10,11). Tissue factor is a receptor for coagulation factor VII and
basal traces of activated factor VII are responsible for the initial tissue factor-factor VIIa
complexes formed (12). The tissue factor-factor VIIa complex together with phospholipids
and calcium ions form a template for activation of coagulation factors IX and X (13).
Activated factor X is rapidly bound by tissue factor pathway inhibitor (TFPI), which then
binds to the tissue factor-factor VIIa complex. This results in the formation of an inactive
quarternary complex (tissue factor, factor VIIa, factor Xa and TFPI) that can no longer sustain
coagulation via the extrinsic pathway (14). For continuation of the coagulation cascade,
activation of factor IX via the intrinsic pathway is necessary (Figure 1).
The intrinsic pathway of coagulation is initiated by the exposure of blood to negatively
charged surfaces (15-17), in a process called contact activation. Ex vivo these negatively
charged surfaces can be glass or kaolin. In vivo these negatively charged surfaces are
unknown but may include subendothelial collagen and may also be provided by endothelial
cells and activated platelets expressing negatively charged phospholipids on the outer
membrane leaflet (18). On negatively charged surfaces as a template, coagulation factor XII
becomes activated by kallikrein, and factor XIIa subsequently activates factor XI. In this
activation process, high molecular weight kininogen serves as an accelerating cofactor. The
physiological role of contact activation is unclear, since a deficiency of factor XII,
prekallikrein or high molecular weight kininogen does not result in bleeding disorders (19).
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Figure 1. Schematic presentation of the coagulation system.
The coagulation cascade is initiated by the extrinsic pathway via the tissue factor-factor
VIIa complex (TF-VIIa) that leads to formation of activated factor X (Xa). Activation of the
extrinsic pathway is inhibited by tissue factor pathway inhibitor (TFPI). With activated
factor V (Va) as a cofactor, factor Xa leads to the formation of thrombin (IIa). Thrombin
activates factor XI and activated factor XI (XIa) triggers the intrinsic pathway. Factor XI
can also be activated via contact activation in the presence of negatively charged
surfaces (such as glass or kaolin) but the contact system plays no significant role in
coagulation in vivo under normal circumstances. The intrinsic pathway sustains
coagulation via the formation of factor Xa that leads to amplification of thrombin
formation. Thrombin finally leads to the deposition of a fibrin clot. After wound healing, the
fibrin clot is degraded by the fibrinolytic system. To prevent premature degradation of a
fibrin clot, fibrinolysis is inhibited by activated thrombin-activatable fibrinolysis inhibitor
(TAFI). Activation of TAFI is mediated by the complex between thrombin and its
endothelial receptor thrombomodulin (TM). Arrows indicate activation, dotted arrows
indicate inhibition (Adapted from Bouma et al., Thromb Haemost 1998; 80: 24-27).
Factor XI is also activated by thrombin, and this activation step forms an important
feedback loop for amplified thrombin formation via the intrinsic pathway (20-24). Factor XIa
activates factor IX, and factor IXa is necessary for continuation of the coagulation cascade via
the activation of factor X via the intrinsic factor X activating (also called tenase) complex
(9,25). At high tissue factor concentrations, activation of factor X mainly occurs via the
extrinsic pathway (13), whereas factor X activation via the intrinsic tenase complex becomes
pronounced at low tissue factor concentrations (26). Continuation of coagulation via the
intrinsic pathway results in amplification of thrombin formation that will finally lead to
deposition of a fibrin clot.
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The intrinsic tenase and prothrombinase complex
Factor IX activated either via the extrinsic (tissue factor-factor VIIa) or intrinsic pathway
activates factor X. Bound to negatively charged phospholipids via calcium ions, a complex is
formed between the enzyme factor IXa, the substrate factor X and a non-enzymatic cofactor
factor VIIIa. This factor X-activating complex is called the intrinsic tenase complex. In the
tenase complex, factor VIIIa is an important cofactor to factor IXa, accelerating the factor
IXa-mediated conversion of factor X to Xa by several orders of magnitude (Figure 2).
Figure 2. The intrinsic tenase and prothrombinase complex.
In the intrinsic tenase complex, coagulation factor X (X) is activated by activated factor IX
(IXa). The enzymatic conversion is enhanced by activated factor VIII (VIIIa). Activated
factor X (Xa) subsequently converts prothrombin (II) into thrombin (IIa) in the
prothrombinase complex. In the prothrombinase complex, activated factor V (Va) serves
as a cofactor, accelerating the activation. Assembly of the intrinsic tenase and
prothrombinase complexes is enhanced by binding of the coagulation factors to
negatively charged phospholipids (indicated by dark spheres in the phospholipid surface)
via calcium ions.
Factor X activated either via the extrinsic or intrinsic pathway activates prothrombin (also
called coagulation factor II). Bound to negatively charged phospholipids via calcium ions, a
complex is formed between the enzyme factor Xa, the substrate prothrombin and a non-
enzymatic cofactor factor Va. Similar to the tenase complex, this prothrombin-activating
complex is called the prothrombinase complex. In the prothrombinase complex, factor Va is
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an important cofactor to factor Xa, accelerating the factor Xa-mediated conversion of
prothrombin to thrombin by several orders of magnitude (see references 9 and 25 for review).
Thrombin: the final step in coagulation
Once prothrombin is activated to thrombin in the prothrombinase complex, it rapidly
activates factors VIII and V. Factors VIIIa and Va are the active cofactors that specifically
increase the intrinsic tenase and prothrombinase activity, respectively. By activating factors
VIII and V, thrombin thus stimulates its own formation by a positive feedback regulation.
Thrombin is the final enzyme necessary for fibrin formation by cleaving fibrinogen. The
resulting fibrin monomers start polymerisation leading to deposition of insoluble fibrin
polymers. The fibrin polymers stabilize the plug that initially consisted only of platelets (27).
Components of the fibrinolytic system can bind to fibrin. Thereby fibrin forms a template for
localization and activation of the fibrinolytic system. In the fibrinolytic system, plasminogen
is activated to plasmin, the enzyme that degrades fibrin (28). To p otect the fibrin clot against
degradation (fibrinolysis), thrombin at high concentrations can activate an inhibitor of the
fibrinolytic system. High concentrations of thrombin are provided via the factor XI-mediated
amplification of thrombin formation that protects the clot against fibrinolysis (22). The
inhibitor of fibrinolysis that is activated by thrombin is called thrombin-activatable
fibrinolysis inhibitor: TAFI (29). Activation of TAFI is enhanced by binding of thrombin to a
receptor that is continuously expressed on the endothelial surface: thrombomodulin.
Dependent on its concentration and localization, thrombin has both anti- and procoagulant
activities (30). In normal situations, thrombin is continuously generated at low basal levels
and bound by thrombomodulin. Binding of thrombin to thrombomodulin converts the
procoagulant activity of thrombin to an anticoagulant one by activating the protein C
anticoagulant pathway (31,32). Activation of the protein C anticoagulant pathway results in a
decreased thrombin formation (discussed in the next session) and consequently, activation of
TAFI is inhibited. This results in the inhibition of both formation and protection of a fibrin
clot. High levels of thrombin are procoagulant and protect a formed clot from degradation by
the fibrinolytic system.
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Down regulation of coagulation: the protein C anticoagulant pathway
Down regulation of coagulation is performed by two important mechanisms: plasma
protease inhibitors and the protein C pathway. Activated coagulation factors can be inhibited
directly by several protease inhibitors present in the circulation (for example TFPI,
antithrombin, heparin cofactor II, a2-macroglobulin and a1-antitrypsin, see references 14 and
33 for review). Since the activated enzymatic coagulation factors are serine proteases, their
inhibitors are called serine protease inhibitors or serpins, with the exception of TFPI and a2-
macroglobulin. Binding of an activated coagulation factor to its inhibitor leads to the
formation of an inactive complex that is rapidly cleared from the circulation.
Endothelial cells continuously express a membrane-bound receptor for thrombin:
thrombomodulin. Low basal levels of thrombin are bound by thrombomodulin and this results
in a change in the substrate specificity of thrombin. The procoagulant activity of thrombin (by
activating fibrinogen, platelets, and coagulation factors VIII and V) is thereby changed into an
anticoagulant activity by activating protein C (34,35, Figure 3). Activation of protein C is
probably facilitated by a receptor that presents protein C to its activating thrombin-
thrombomodulin complex (36,37). This recently discovered receptor binds protein C and its
activated form with similar affinity (38).
Figure 3. Activation of the protein C anticoagulant pathway.
On the endothelial surface, protein C (PC) is activated by the thrombin-thrombomodulin
complex (IIa-TM). Activation of protein C is presumably facilitated by the endothelial cell
protein C receptor (EPCR) that presents protein C to the activating thrombin-
thrombomodulin complex. Proteolytic activation of protein C results in the formation of
activated protein C (APC).
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Activated protein C (APC) proteolytically inactivates coagulation factors VIIIa and Va
(39-41) and inactivation is accelerated in the presence of phospholipids. By incorporation of
phosphatidylethanolamine into the lipid surface, the APC-mediated inactivation of factor Va
is selectively enhanced (42). Since factors VIIIa and Va are important cofactors for the
intrinsic tenase and prothrombinase activity, APC is an important regulator of coagulation by
inhibiting the intrinsic tenase and prothrombinase complexes. The importance of protein C is
illustrated by the fact that people with decreased protein C levels have an increased risk for
venous thrombosis (43-47).
Protein S
In the anticoagulant protein C pathway, protein S serves as a cofactor to APC in the
inactivation of coagulation factors VIIIa and Va (48-51, Figure 4). In addition to its cofactor
activity to APC, protein S also has an anticoagulant activity that is independent of APC. The
APC-independent anticoagulant activity of protein S involves the direct inhibition of intrinsic
tenase and prothrombinase activity in itro (52,53). For the APC-independent activity of
protein S, direct interactions of protein S with phospholipids and coagulation factors VIIIa,
Xa and Va are important (54-58). A deficiency in protein S is associated with thrombosis,
indicating the importance of this anticoagulant protein (47,59-61).
The cofactor activity of protein S to APC is expressed by increasing the affinity of APC for
phospholipids (62,63) and relocating the active site of APC closer to the membrane surface
(64). Thereby, protein S localizes APC to its functional site of action: the phospholipid
membrane surface that contains the activated coagulation factors. APC can proteolytically
inactivate factors Va and VIIIa by cleaving these factors at several sites. APC cleavage sites
within factor Va involve residues Arg306, rg506 and Arg679 (65), and the first two cleavage
sites correlate with loss of cofactor activity. Cleavage of factor Va at Arg506 occurs rapidly
and results in a factor Va molecule with an intermediate cofactor activity. Cleavage at Arg306
occurs slowly and results in a total abrogation of factor Va cofactor activity (66). Relocation
of the APC active site by protein S probably localizes it closer to the Arg306 site of factor Va,
thereby promoting a cleavage that results in total inhibition of factor Va cofactor activity. By
this mechanism, protein S stimulates inactivation of factor Va about 20-fold (67). A naturally
occurring mutation in the factor V gene causes a change in amino acid residue 506 from Arg
to Gln (68-70). This mutation (factor VR506Q or factor VLeiden) causes the affected factor V
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molecule to become insensitive to inactivation by APC-mediated cleavage at the 506 site,
called APC resistance (71). Consequently, people carrying this mutation have an increased
risk for venous thrombosis caused by an impaired anticoagulant pathway (72,73).
Figure 4. Inactivation of activated factors V and VIII by activated protein C.
Bound to negatively charged phospholipids (indicated by dark spheres in the
phospholipid surface), activated protein C (APC) proteolytically inactivates activated
factors V (Va) and VIII (VIIIa). Binding of APC to the phospholipid surface is facilitated by
its cofactor protein S (PS). Protein S accelerates the inactivation of factors Va and VIIIa, a
process that is inhibited by binding of protein S to C4b-binding protein (C4BP). In the
inactivation of factor VIIIa, factor V and protein S act as synergistic cofactors to APC.
While the APC anticoagulant activity is stimulated by protein S, it is inhibited by factor Xa
(40,67,74,75). Factor Xa protects factor Va from cleavage by APC at the Arg506 site. This
protective effect is abolished by protein S by specifically accelerating cleavage at the Arg306
site (56,76).
So far, studies concerning the APC anticoagulant activity have mainly focussed on the
inactivation of factor Va (reviewed in reference 77). Probably, the mechanism of cofactor
activity of protein S to APC in the inactivation of factor VIIIa involves a similar mechanism
as described for factor Va. APC cleavage sites within factor VIIIa involve residues Arg336,
Arg562 and Arg740, and the first two cleavage sites are considered to be important in the APC-
mediated degradation (78-80). Cleavage of factor VIIIa at Arg562 occurs rapidly and correlates
best with inactivation of factor VIIIa, while cleavage at Arg336 occurs slowly. Protein S
enhances APC-mediated cleavage at the Arg562 site (48,49,51), and factor V can further
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increase the effect of protein S (81-84). The increase in APC activity by factor V is only
expressed in the presence of protein S. Thus, factor V and protein S act as synergistic
cofactors to APC in the degradation of factor VIIIa. Factor VR506Q has less synergistic
cofactor activity with protein S in the APC-mediated inactivation of factor VIIIa (84,85),
indicating that APC-mediated cleavage of factor V at the Arg506 site is necessary to express
anticoagulant activity. Consequently, factor VR506Q causes an increased risk for venous
thrombosis by resistance to APC-mediated inactivation and by an impaired synergistic
cofactor activity with protein S in the inactivation of factor VIIIa. It remains to be elucidated
if factor V also enhances the APC-mediated inactivation of factor Va similar to the
mechanism described for the inactivation of factor VIIIa. In contrast to factor V, no mutations
haven been found so far in the APC cleavage sites in factor VIIIa that result in resistance to
APC-mediated inactivation (86). While the APC anticoagulant activity is stimulated by
protein S, it is inhibited by factor IXa (87,88). Factor IXa cleaves factor VIIIa at Arg336,
involving binding of factor IXa to the Arg562 site. By binding to this site, factor IXa prevents
APC-mediated cleavage at the Arg562 site (89,90). This protective effect is abolished by
protein S by specifically accelerating the APC-mediated cleavage at the Arg562 site. Factor
VIII is protected by von Willebrand factor against APC-mediated proteolytic inactivation
(87,91,92).
C4b-binding protein (C4BP)
The cofactor activity of protein S to APC is regulated by two mechanisms. Thrombin
cleaves protein S in the so-called thrombin sensitive region. Thrombin cleavage sites involve
residues Arg49, Arg60 and Arg70 in human protein S (93). Thrombin-cleaved protein S loses its
cofactor activity to APC, and has reduced calcium and phospholipid-binding properties (94-
97). Calcium ions protect protein S against thrombin-mediated cleavage (98), thus it seems
unlikely that thrombin cleaves protein S in v vo. However, increased levels of cleaved protein
S are detected in patients with disseminated intravascular coagulation (99). Prob bly, other
proteases exist that cleave protein S during intravascular coagulation (100).
In addition to proteolytic inactivation, protein S cofactor activity is regulated by binding to
C4b-binding protein (C4BP, 101-103). C4BP is a regulator of the classical pathway of the
complement system (104-109). The complement system is a complex cascade of proteins that
is activated upon infection by pathogens. The role of the complement system is to initiate
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inflammation, neutralize pathogens and to provide clearance of immune complexes from the
circulation (110,111). Activation of the classical pathway of complement can occur via the
binding of antigen-antibody complexes to the initial component of the classical pathway of
the complement system: C1. During complement activation, component C4 is cleaved into
C4a and C4b. C4b is necessary for continuation of the complement cascade, that finally leads
to the formation of a so-called membrane attack complex of complement proteins on the
surface of cells. The membrane attack complex forms a transmembrane channel that permits
free exchange of solutes, finally resulting in cell lysis. It is evident that only foreign cells
should be attacked by the complement system, and thus regulation of complement activation
is crucial. As a mechanism of down regulation of complement activation, C4b is bound to
C4BP. C4BP acts as a cofactor to factor I in the proteolytic degradation of C4b
(105,106,108,112), and accelerates the decay rate of the C4b2a complex, an intermediate
complex that is formed during classical complement activation (107,113). C4BP is expressed
in the liver (114), and in normal situations plasma levels are 260 nM (150 mg/ml, 115).
During a complex series of events that can be triggered upon inflammation, infection or tissue
damage (so-called acute phase response), C4BP levels can increase up to four-fold (116,117).
Due to its up regulation during an acute phase response, C4BP is called an acute phase
reactant.
In addition to its regulatory function in complement activation via binding to C4b, C4BP
also noncovalently binds to protein S (118). The protein S-C4BP interaction is a high affinity
1:1 stoichiometric interaction that is calcium dependent (119). Approximately 60% of protein
S is in a reversible complex with C4BP that results in an inhibition of protein S cofactor
activity to APC (101-103). Binding of protein S to phospholipids is unaffected by C4BP and
the complex is still able to bind to APC (103). C4BP inhibits the binding of protein S to
coagulation factor V(a), which may explain the inhibition of protein S cofactor activity to
APC in the inactivation of factor Va and the protein S/factor V synergistic cofactor activity in
the inactivation of factor VIIIa (57).
Structure of C4BP
C4BP is a glycoprotein previously named C3b-C4bINA cofactor (108) nd was found to
be identical to proline-rich protein (120-122). C4BP contains six or seven identical a-ch ins
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and a single b-chain, although 17% (45 nM) of the C4BP molecules lack the b-chain (115).
Thereby, different isoforms exist in plasma, and two major isoforms that are distinguished are
C4BP-high and C4BP-low (123). C4BP-high accounts for up to 80% of total C4BP and has a
molecular weight of approximately 570 kDa, containing seven a-chains and one b-chain
(a7b1). C4BP-low has a molecular weight of approximately 530 kDa and contains two
isoforms: one that contains six a-chains with one b-chain (a6b1) and one that contains seven
a-chains without a b-chain (a7b0). Each a-chain contains 549 amino acids and has a
molecular weight of 70 kDa (124-126). The b-chain contains 235 amino acids and has a
molecular weight of 45 kDa. Due to high glycosylation of the b-chain, this additional subunit
was discovered only recently and was found to contain the protein S-binding site (127,128).
Before the discovery of the b-chain, it was thought that protein S bound to C4BP via the a-
chains (129). Expression of C4BP a- and b-chains is differentially regulated, and during an
acute phase response, an increase in a-chain expression predominates. Due to the differential
regulation of a- and b-chain expression, b-chain containing C4BP levels are held at stable
levels and thus, free protein S levels remain stable even during an acute phase response
(130,131). However, several studies report patients with increased C4BP levels, which may
account for part of the thrombotic complications of these patients due to decreased levels of
free protein S (117,132-137). Familial C4BP deficiency is described in several patients,
resulting in increased levels of free protein S (138-141). In term and preterm infants, low
levels of C4BP are normal, resulting in high levels of free protein S (142,143).
Each a-chain contains one binding site for C4b in its amino-terminal region, and no more
than four molecules of C4b can bind to a single C4BP molecule, probably due to steric
hindrance of the remaining C4b-binding sites (144-148). The a- and b-chain are both
composed of repeating homologous domains of approximately 60 amino acids that are
commonly found in complement regulatory proteins: short consensus repeats (SCRs) or Sushi
domains (149-152). Due to the presence of SCRs in many complement regulatory proteins
(for example factor H, decay accelerating factor, complement receptors CR1 and CR2,
complement components C1r, C1s, C2, C6 and C7), these domains are also called
complement control protein (CCP) modules. However, these modules are also found in
proteins that are not involved in the regulation of the complement system, for example
coagulation factor XIII and b2-glycoprotein I. The function of the SCRs in these
noncomplement regulatory proteins is unknown.
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In general, SCRs are individually encoded by single exons (128). Each SCR contains four
cysteine residues that form disulfide bridges in a 1-3 and 2-4 conformation (149). Thereby,
SCRs form a typical double loop structure. By repeating SCR units, an elongated structure is
formed. The a-chain of C4BP contains eight SCRs, the b-chain three. The binding site of C4b
involves the amino-terminal SCR of the C4BP a-chain(148). The binding site of protein S is
localized in the first amino-terminal SCR of the C4BP b-chain, involving residues 34-42
(153-156). In their carboxy-terminal region, both the a- and b-chain contain a nonrepeat
domain of approximately 60 amino acid residues that contains two cysteine residues. These
two carboxy-terminal cysteine residues cause the interchain disulfide bridge that covalently
links the a- and b-subunits of the C4BP molecule (128, Figure 5).
Figure 5. Schematic presentation of the a- and b-chains that comprise the C4b-
binding protein (C4BP) molecule.
Each chain contains homologous short consensus repeats (SCRs) followed by a carboxy-
terminal nonrepeat domain. The carboxy-terminal nonrepeat domain contains two
cysteine residues (indicated by arrows) that covalently link the a- and b- subunits. By a
mechanism that is still unknown, C4BP molecules always contain 6 or 7 a-chains with no
or only a single b-chain. The b-chain contains the protein S binding site (Adapted from
Hillarp and Dahlbäck, Proc Natl Acad Sci USA 1990; 87: 1183-1187).
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The reason why a C4BP molecule never contains more that one b-chain is unclear.
Apparently, C4BP synthesis in the liver involves a process that always combines one b- hain
subunit with six or seven a-chain subunits. It is most likely that during assembly of the C4BP
isoforms that lack the b-chain, only a-chains are incorporated. Alternatively, these C4BP
isoforms may result from proteolytic cleavage of a single b-chain after incorporation into the
C4BP molecule. In electron microscopic studies, the C4BP molecule appears as an octopus or
spider-like structure, with the a- chains (and the b-chain) extending like tentacles from the so-
called core region (144,157,158). In solution however, the molecule is a bundle of extended
arms that are held close together (159).
Due to the localization of the protein S-binding site on the b-chain, C4BP isoforms that
lack the b-chain have no protein S-binding ability (160). Thus, the amount of protein S that is
in complex with C4BP is determined by the amount of C4BP isoforms that contain a b-chain
(C4BPb+). Since almost all C4BPb+ isoforms are in complex with protein S, free protein S is
the result of molar excess of protein S over C4BPb+ (115). It is interesting to note that there is
a relation between species specific C4BP subunit composition and protein S binding ability.
Bovine C4BP lacks the first amino-terminal SCR of the b-chain and consequently, has no
complex formation between C4BP and protein S (161). In rabbits and mice, the C4BP b-chain
has evolved into a pseudogene, resulting in the absence of the entire b-chain and thus, rabbit
and mouse C4BP lack the ability to bind to protein S (162-164). Rat C4BP contains a b-chain,
but the first amino-terminal SCR lacks one out of four cysteine residues (165). The mi sing
cysteine residue corresponds to the third amino-terminal cysteine residue in the human C4BP
b-chain, which may account for the decreased binding affinity between protein S and C4BP in
rat plasma.
The binding site for C4BP on protein S has been localized in the carboxy-terminal domain
of protein S. This domain is homologous to sex hormone binding globulin (SHBG) and is
therefore called the SHBG-like domain (166-168). The exact binding site for C4BP on the
SHBG-like domain of protein S is still unknown, but most likely involves more than one
binding region (Figure 6). Several domains within the SHBG-like domain have been
postulated to be involved in the interaction of protein S with C4BP, including regions 408-
434 (169-171), 447-460 (172), and 583-635 (173-177).
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Figure 6. Schematic presentation of human protein S.
From the amino-terminus to the carboxy-terminus, the protein contains a Gla-domain with
g-carboxylated Gla residues (indicated by Y), a thrombin sensitive region with three
thrombin cleavage sites (indicated by Th), four epidermal growth factor (EGF)-like
domains and the sex hormone binding globulin (SHBG)-like domain. OH denotes b-
hydroxyaspartic acid or b-hydroxyasparagine residues. Triangles indicate carbohydrate
side chains. The SHBG-like domain is the C4BP binding region, with the putative binding
sites indicated by hatched sections (Adapted Dahlbäck, Thrombosis Research 1995; 77:
1-43).
Interactions of C4BP with other components
Other components than protein S and complement C4b can bind to C4BP. Serum amyloid
P component (SAP) binds in a 1:1 stoichiometry to the central core of C4BP (178-180) and
this interaction is also calcium dependent. SAP is closely related to C-reactive protein (CRP).
Like C4BP, CRP is an acute phase reactant, and SAP and CRP belong to the pent(r)axin
protein family (181,182). SAP inhibits the binding of C4b to C4BP, and thereby SAP may
provide a fine-tuning regulatory mechanism of complement activation by decreasing the
inactivation of C4b (183). Heparin binds to C4BP at the C4b-binding site in a calcium-
dependent manner (184-186). Like SAP, binding of heparin to C4BP results in the inhibition
of C4b binding to C4BP. Heparin (released by mast cells during inflammation or tissue
damage) may therefore also be involved in a fine-tuning regulation of complement activation.
C4BP has also been found to bind to bacterial surface proteins from Streptococcus pyogenes
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(187,188). Possibly, this bacterium has evolved the mechanism of binding a complement
inhibitory protein to evade the host defence system (189). Finally, C4BP also binds to
coagulation factor VIII (190). Together with protein S, binding of C4BP to factor VIII results
in a synergistic inhibition of intrinsic tenase activity that is independent of protein C.
Aim of the study
In summary, C4BP is a protein that in eracts with several components. The name of the
protein is based on the primary discovery of its interaction with complement component C4b
(191,192). Binding of C4b to C4BP results in inhibition of complement activation (105-
108,113), a process that can be inhibited by binding of SAP or heparin to C4BP (183,185).
C4BP binds to coagulation factor VIII and in synergy with protein S, this results in inhibition
of intrinsic tenase activity that is independent of anticoagulant APC (190). Thereby, C4BP has
an anticoagulant effect. Protein S binds to C4BP and this results in an inhibition of the APC-
dependent cofactor activity of protein S (101-103). By inhibiting an anticoagulant pathway,
C4BP has a procoagulant effect. This study will focus on the interaction between protein S
and C4BP and the functional effects of this interaction on the protein C anticoagulant
pathway. In this thesis, the following topics will be discussed:
Does the first amino-terminal SCR of the C4BP b-chain contain the complete binding
site for protein S, or do the other SCRs also play a role in the interaction of protein S
with the b-chain?
This topic will be discussed in chapters two and three. To study the interaction of
protein S with C4BP, chimeras have been constructed that contain the SCRs derived
from the b-chain of C4BP fused to the amino-terminus of a modified tissue
plasminogen activator (tPA).
What is the effect of binding of protein S to C4BP on the protein S cofactor activity to
APC in the inactivation of factor VIIIa?
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So far, the effect of complex formation between protein S and C4BP on the cofactor
activity of protein S has only been studied in purified systems that measure protein S
cofactor activity to APC in the inactivation of factor Va or in plasma systems that
measure overall protein S cofactor activity. The effect of protein S-C4BP complex
formation on the protein S cofactor activity to APC in the inactivation of factor VIIIa
was studied in a purified system and will be discussed in chapter four.
Does C4BP have an effect on the protein C anticoagulant pathway that is independent of
the complex formation with protein S?
Protein S has an anticoagulant effect that is independent of APC by the inhibition of the
intrinsic tenase and prothrombinase activity. The APC-independent inhibition of the
tenase activity by protein S is enhanced by C4BP. In chapter five, the effect of C4BP on
the APC-mediated factor Va inactivation was studied that is independent of protein S.
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Chapter 2
Interaction between protein S and complement C4b-binding
protein (C4BP). Affinity studies using chimeras containing C4BP
b-chain short consensus repeats
Robbert H. L. van de Poel1, Joost C. M. Meijers1,2 and Bonno N. Bouma1
1 Thrombosis and Haemostasis Laboratory, Department of Haematology, University Medical
Center, Utrecht, and the Institute of Biomembranes, Utrecht University, The Netherlands
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The Netherlands
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Summary
Human C4b-binding protein (C4BP) is a regulator of the complement system and plays an
important role in the regulation of the anticoagulant protein C pathway. C4BP can bind
anticoagulant protein S, resulting in a decreased cofactor function of protein S for activated
protein C. C4BP is a multimeric protein containing several identical a-chains and a single b-
chain (C4BPb), each chain being composed of short consensus repeats (SCRs). Previous
studies have localized the protein S binding site to the NH2-terminal SCR (SCR-1) of C4BPb.
To further localize the protein S binding site, we constructed chimeras containing C4BPb
SCR-1, SCR-2, SCR-3, SCR-1+2, SCR-1+3 and SCR-2+3 fused to tissue-type plasminogen
activator. Binding assays of protein S with these chimeras indicated that SCR-2 contributes to
the interaction of protein S with SCR-1, since the affinity of protein S for SCR-1+2 was up to
5-fold higher compared with SCR-1 and SCR-1+3. Using an assay that measures protein S
cofactor activity, we showed that cofactor activity was decreased due to binding to constructs
that contain SCR-1. SCR-1+2 inhibited more potently than SCR-1 and SCR-1+3. SCR-3 had
no additional effect on SCR-1 and therefore the effect of SCR-2 was specific. In conclusion,
b-chain SCR-2 contributes to the interaction of C4BP with protein S.
Introduction
C4b-binding protein (C4BP) is an important regulator of the complement system (104-
107,109). It accelerates C2a decay from the classical pathway C3-convertase (C4b2a)
complex (107,113), and promotes factor I-mediated degradation of C4b (105-107,112). C4BP
also has a high affinity for anticoagulant vitamin K-dependent protein S, and together they
form a noncovalent 1:1 stoichiometric complex (118,119,193,194). Binding of protein S to
C4BP results in a decreased cofactor function of protein S for anticoagulant activated protein
C (APC) in the degradation of coagulation factors Va and VIIIa (102,195,196). Complex
formation between protein S and C4BP has no effect on the inhibition of complement
activation. C4BP is a multimeric glycoprotein (Mr 530,000-570,000), composed of six or
seven identical a-chains, and approximately 80-85% of C4BP contains an additional single b-
chain that binds protein S (115,193,197). In their COOH-terminal regions, the a- and b-
chains contain cysteine residues that form the interchain disulfide bridges in the so called core
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region (128). In electron microscopy studies, C4BP has an octopus-like appearance
(144,157,158). Under normal conditions, approximately 60% of total protein S is bound to
C4BP, and 40% is free (130). During an acute phase response, C4BP levels can increase up to
4-fold. Due to a mechanism of differential regulation of a- and b-chain expression, an
increase of a-chains predominates during such an acute phase response, and hence free
protein S is held at stable levels (130). The a-chains (Mr 70,000) are composed of eight
homologous domains called short consensus repeats (SCRs, 125,128). SCRs are commonly
found structures in complement regulatory proteins such as factor H and decay acceleration
factor in which the SCR units have complement C3b/C4b binding properties (149). However,
noncomplement regulatory proteins have also been found containing SCR units such as b2-
glycoprotein I and the b-subunit of coagulation factor XIII in which the function of the SCR
units are unknown (for reviews, see references 149 and 150). The b-chain (Mr 45,000) is
composed of three SCR units, and previous studies have shown the protein S binding site to
be localized within the NH2-terminal SCR unit (SCR-1) of the b-chain (153-156). In this
study, recombinant chimeras were constructed composed of each individual b-chai  SCR nit
and combinations of SCR units (SCR-1+2, SCR-1+3 and SCR-2+3) fused to the NH2-
terminus of a modified tissue plasminogen activator (tPA) in which the serine residue was
replaced by an alanine residue (198). This inactive tPA module is well characterized and has
been proven in previous studies to be a useful tool to investigate the function of protein
domains (198-200). The aim of this study was to investigate the role of each individual b-
chain SCR unit in the interaction between protein S and C4BP. Studies using chimeric SCR-
tPA constructs show that SCR-2 of C4BP b-chain is involved in the interaction of protein S
with SCR-1.
Methods
Proteins
C4BP was immunopurified from human plasma as described by Hessing et al. (160).
Protein C was purified and activated as described previously (91). Pr tein S was purified from
prothrombin concentrates as described by Hackeng et al. (201).
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Chimeric SCR-tPA constructs
Each individual b-chain SCR unit and adjacent SCR units (SCR-1+2 and SCR-2+3) were
amplified using wildtype recombinant C4BP b-chain. This construct was made by PCR
amplification from a human liver cDNA library using oligonucleotides C4BPbF (5'
TTTGAATTCTGGGGAGAGGACTTTGATCAC 3') and C4BPbR (5'
TTTGAATTCTATTACATCTGCTCAGCTGTA 3'). After amplification, the PCR product
was cleaved with EcoRI (underlined) and cloned in EcoRI-cleaved expression vector
pcDNA3 (Invitrogen, Leek, The Netherlands). The sequence and orientation of the amplified
region of this construct was confirmed by dideoxy sequencing. This construct was designated
pcDNA3-C4BPb. PCR strategies for amplification of SCR units from pcDNA3-C4BPb were
based on the intron/exon organization of the C4BPb g ne as described (202) with the primers
depicted in Table I. For the amplification of SCR-1+3, a modified C4BPb was used that
lacked SCR-2 (pcDNA3-C4BPbDSCR-2 in Table I). The construct pcDNA3-C4BPbDSCR-2
was made using AvaII-cleaved pcDNA3-C4BPb as a template. SCR-3 and the carboxy-
terminal end of the b-chain was amplified using oligonucleotide C4BPbR in combination
with an oligonucleotide that linked the 3’ coding region of SCR-1 (in capital letters) with the
5’ coding region of SCR-3 (in small letters):
ACACCACTACTGAGTGCCGCagggactgtgaccctcctgggaat. The PCR product was isolated
and used in combination with oligonucleotide C4BPbF and AvaII-cleaved pcDNA3-C4BPb to
amplify the leader peptide and SCR-1 of the b-chain. After isolation, the PCR product
containing adjacent SCR-1 and SCR-3 was further amplified using oligonucleotides C4BPbF
and C4BPbR. This PCR product was cleaved with EcoRI and cloned in EcoRI-cleaved
pcDNA3. The sequence and orientation of the amplified region of pcDNA3-C4BPbDSCR-2
was confirmed by dideoxy sequencing. After amplification of SCR units, PCR products were
cleaved with BglII/XhoI and cloned in BglII/XhoI-cleaved expression vector ZpL7 containing
a modified tPA (199). These chimeric SCR-tPA constructs were designated SCR-1, SCR-2,
SCR-3, SCR-1+2, SCR-1+3 and SCR-2+3, respectively. The sequence of the amplified
regions of all constructs was confirmed by dideoxy sequencing.
30
Table I. Oligonucleotide sequences used for PCR amplification.
The template used for each PCR amplification is shown at the bottom of the table. Wild
type recombinant C4BPb is depicted as pcDNA3-C4BPb. Recombinant C4BPb lacking
the second NH2-terminal SCR unit is depicted as pcDNA3-C4BPbDSCR-2. In the left
column, forward primers are denoted by the letter F, and backward primers are denoted
by the letter R. In the second column, nucleotide sequences of the primers are shown.
Boldface, BglII restriction site. Underlined, XhoI restriction site. On top of the six outmost
right columns, the different b-chain SCR unit chimeras are depicted by numbers equal to
the corresponding b-chain SCR units contained within the chimeras. Combinations of
template DNA and primers used for amplification of the different chimeras are indicated
by dots.
Cell culture, transfection, and purification of recombinant constructs
Transfection of baby hamster kidney cells was performed as described previously (203).
Expression of all constructs was performed in conditioned medium (CHO-II-SFM; Life
Technologies, Inc., Paisley, U.K.), and harvested medium was stored at –20 oC until needed
for further use. Purification of chimeric SCR-tPA constructs was performed as described
previously (198) using a monoclonal antibody against tPA. Concentrations of chimeric SCR-
tPA constructs were determined using an ELISA system that determines tPA concentration
(ImulyseTM tPA; Biopool, Umeå, Sweden). Purified constructs were applied to 10% SDS-
PAGE under reducing and nonreducing conditions, and stained by Coommassie Brilliant Blue
or transferred to polyvinylidene difluoride membrane (Millipore Corp., Bedford, MA) for
standard Western blotting procedures using sheep-anti-tPA antibodies (1 µg/ml; Enzyme
Research Laboratories Inc.) followed by a polyclonal peroxidase-conjugated antibody against
sheep antibodies (Dako, Glostrup, Denmark).
SCR-tPA construct
Primer Sequence 1 2 3 1+2 1+3 2+3
C4BPb1F 5' TTT AGA TCT  GAG CAC TGT CCA GAG CTT CCT 3' • • •
C4BPb1R 5' T TTC TCG AGT GCG GCA CTC AGT AGT GGT GT 3' •
C4BPb2F 5' TTT AGA TCT  TTG GGC CAC TGT CCT GAT CCT 3' • •
C4BPb2R 5' T TTC TCG AGT ACT TTT GCA GAT GGG AAA GG 3' • •
C4BPb3F 5' TTT AGA TCT  AGG GAC TGT GAC CCT CCT GGG 3' •
C4BPb3R • • •
Template pcDNA3-C4BPb • • • • •
pcDNA3-C4BPbDSCR-2 •
5' T TTC TCG AGT CAA CTT GCA GAC TGG AAG TG 3'
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Binding of protein S to immobilized chimeric SCR-tPA constructs
The binding of protein S to immobilized chimeric SCR-tPA constructs was performed as
follows. Microtiter plates (96-well vinyl assay plates; catalog no. 2595, Costar, Cambridge,
MA) were coated overnight at 4 oC with a polyclonal antibody against tissue plasminogen
activator (5 µg/ml; ImulyseTM-tPA, Biopool AB) in coat buffer (15 mM Na2CO3.10 H2O, 35
mM NaHCO3, pH 9.6), 50 µl/well. Plates were washed three times with Tris-buffered saline
(TBS; 50 mM Tris-HCl, pH 7.4, 150 mM NaCl) containing 0.1% (v/v) Tween 20. Plates were
blocked for 2 h at 37 oC with TBS containing 3% (w/v) bovine serum albumin (blocking
buffer), 100 µl/well. CHO-II-SFM supernatant derived from baby hamster kidney cells
transfected with the constructs described above was then added to the wells and incubated for
2 h at 37 oC in blocking buffer containing 0.1% Tween 20, 50 µl/well. After washing three
times with TBS containing 0.1% Tween 20, increasing concentrations of protein S were added
to the wells and incubated for 2 h at 37 oC in blocking buffer containing 0.1% Tween 20 and 5
mM CaCl2, 50 µl/well. Plates were washed three times with TBS containing 0.1% Tween 20
and bound protein S was detected using a polyclonal peroxidase-conjugated antibody against
protein S (1.3 g/liter IgG; Dako), 1:2000 diluted in blocking buffer containing 0.1% Tween 20
and 5 mM CaCl2, 50 µl/well. After washing three times with TBS containing 0.1% Tween 20,
staining solution consisting of 0.4 mg/ml o-phenylenediamine and 0.002% H2O2 in 100 mM
phosphate, 50 mM citric acid buffer (pH 5.0) was added to the wells (100 µl/well). The
reaction was stopped by adding 50 µl/well 1 M H2SO4,and absorbance was measured at 490
nm in a Vmax microtiter plate reader (Molecular Devices, Menlo Park, CA). Values were
corrected for background absorbance.
Binding of chimeric SCR-tPA constructs to immobilized protein S
Microtiter plates were coated overnight at 4 oC with a polyclonal antibody against protein
S (3 g/liter IgG; DAKO), 1:1000 diluted in coat buffer, 50 µl/well. Plates were washed three
times with TBS containing 0.1% Tween 20. Plates were blocked for 2 h at 37 oC wit
blocking buffer, 100 µl/well. Purified human protein S (1 µg/ml) was added to the wells and
incubated in blocking buffer containing 0.1% Tween 20 and 5 mM CaCl2 for 2 h at 37 oC, 50
µl/well. Plates were washed three times with TBS containing 0.1% Tween 20 and increasing
concentrations of purified chimeric SCR-tPA constructs were added and incubated for 2 h at
37 oC in blocking buffer containing 0.1% Tween 20 and 5 mM CaCl2, 50 µl/well. After
washing the plates three times with TBS containing 0.1% Tween 20, sheep-anti-tPA
antibodies (1 µg/ml; Enzyme Research Laboratories Inc.) were added in blocking buffer
32
containing 0.1% Tween 20 and 5 mM CaCl2, 50 µ /well. After 1 h of incubation at 37 oC,
plates were washed three times with TBS containing 0.1% Tween 20. Bound sheep antibodies
against tPA were detected by adding a polyclonal peroxidase-conjugated rabbit antibody
against sheep antibodies (Dako), 1:1000 diluted in blocking buffer containing 0.1% Tween 20
and 5 mM CaCl2, 50 µl/well. After washing three times with TBS containing 0.1% Tween 20,
the wells were developed and measured as described above. Values were corrected for
background absorbance.
Stoichiometry of the interaction between protein S and SCR-tPA constructs
A fluid phase binding assay was used to investigate the stoichiometry of the interaction
between protein S and the SCR-tPA constructs that bound to protein S. For this assay, 5 mg of
purified rabbit antibodies directed against human protein S (Dako) was coupled to 2.5 ml of
CNBr activated Sepharose 4B (Amersham Pharmacia Biotech AB, Uppsala, Sweden)
according to the manufacturer’s instructions. Fluid phase binding was performed by allowing
increasing concentrations of SCR-tPA constructs to bind to 10 nM human protein S in a
volume of 100 µl of TBS containing 5% bovine serum albumin and 10 mM CaCl2. Binding
was performed overnight at 4 oC with constant rotation. Then 100 µl of rabbit anti-human
protein S-Sepharose beads in TBS was added (final CaCl2 concentration 5 mM). After 90 min
of incubation with constant rotation at room temperature, total protein S was removed from
the incubation mixture by spinning down the Sepharose beads in an Eppendorf centrifuge for
3 min at 14,000 rpm. The supernatant was analyzed with a polyclonal tPA ELISA
(ImulyseTM-tPA, Biopool AB) for nonbound (free) SCR-tPA constructs. As a control, the
supernatant was also analyzed with a polyclonal protein S ELISA to confirm that all of the
protein S was precipitated by the Sepharose beads. In this polyclonal ELISA, rabbit anti-
protein S antibodies were used as catching antibodies and peroxidase-conjugated rabbit anti-
protein S antibodies were used as detecting antibodies (antibodies from Dako).
Competition experiments using chimeric SCR-tPA constructs for binding of protein S
to immobilized C4BP
Microtiter plates were coated overnight at 4 oC with a monoclonal antibody against C4BPa
(8C11) in coat buffer, 2 µg/ml, 50 µl/well. Plates were washed three times with TBS
containing 0.1% Tween 20. Plates were blocked for 2 h at 37 oC with blocking buffer, 100
µl/well. Purified human C4BP (2 µg/ml) was incubated in blocking buffer for 1 h at 37 oC.
Purified human protein S (0.5 nM) was preincubated with chimeric SCR-tPA constructs (0-
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400 nM) for 1 h at 37 oC in blocking buffer containing 5 mM CaCl2. After washing the plates
three times with TBS containing 0.1% Tween 20, aliquots of 50 µl from the preincubation
mixtures were applied to the plates and incubated for 2 h at 37 oC. After washing three times
with TBS containing 0.1% Tween 20, bound protein S was detected using a polyclonal
peroxidase-conjugated antibody against protein S (1.3 g/liter IgG; Dako), 1:2000 diluted in
blocking buffer containing 0.1% Tween 20 and 5 mM CaCl2, 50 µl/well. After washing three
times with TBS containing 0.1% Tween 20, the wells were developed and measured as
described above. Values were corrected for background absorbance.
Protein S cofactor activity in plasma
Protein S cofactor activity was determined with an activated partial thromboplastin time-
based assay using a KC-10A micro coagulometer (Amelung, Lemgo, Germany). For this
assay, plasma deficient in protein S and C4BP was prepared by immunoadsorption as
described previously (57). Purified human protein S (160 nM) was preincubated for 30 min at
37 oC with serial dilutions of chimeric SCR-tPA constructs in TBS containing 0.3% (w/v)
bovine serum albumin plus 3 mM CaCl2. Aliquots of 12.5 µl from the preincubation mixtures
were added to a mixture of 25 µl of plasma deficient in protein S and C4BP and 12.5 µl of
240 nM activated protein C solution (final APC concentration 30 nM). After adding 25 µl
PTT Reagent (Roche Molecular Biochemicals), coagulation was initiated by adding 25 µl of
25 mM CaCl2 (final volume 100 µl). In the range of protein S used in this assay (0-20 nM
protein S), there was a linear relationship between clotting time and protein S concentration
(data not shown). The protein S cofactor activity was expressed as a percentage of the
maximum cofactor activity in the absence of chimeric SCR-tPA constructs.
Results
Expression and purification of chimeric SCR-tPA constructs
In order to study the role of each individual C4BPb SCR unit in the interaction of C4BP
with protein S, chimeras were constructed of b- hain SCR units fused to the NH2-terminus of
a modified tPA. Baby hamster kidney cells were transfected with the expression vector
containing the chimeric SCR-tPA constructs. Expression levels in the medium were detected
using a tPA ELISA system and were 1-5 µg/ml after 3 days of culture. After purification of
the chimeric constructs with an immobilized monoclonal antibody against tPA, the constructs
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were applied to 10% SDS-PAGE under reducing and nonreducing conditions and stained by
Coommassie Brilliant Blue (Figure 1, A and B) or transferred to polyvinylidene difluoride
membrane (Millipore Corp., Bedford, MA) for standard Western blotting procedures using a
polyclonal antibody against tPA (Figure 2, A and B). The chimeric SCR-tPA constructs
appeared as diffuse bands which is probably caused by heterogeneous glycosylation of the
proteins, because the b-chain of C4BP and the tPA module are both highly glycosylated
(128,198). Constructs containing single b-chain SCR units had molecular weights of
approximately 73,000 with the exception of SCR-3, which had an estimated molecular weight
of 65,000. Constructs containing two b-chain SCR units had molecular weights of
approximately 80,000. The chimeric SCR-tPA constructs were also detected by Western
blotting using a polyclonal antibody against tPA (Figure 2, A and B).
Figure 1. SDS-PAGE of chimeric SCR-tPA constructs.
Purified chimeric SCR-tPA constructs (1.5 mg) were applied to 10% SDS-polyacrylamide
gel under nonreducing (A) and reducing conditions (B). Proteins were visualized by
Coommassie Brilliant Blue staining. Lane 1, SCR-1-tPA; lane 2, SCR-2-tPA; lane 3, SCR-
3-tPA; lanes 4 and 8: molecular weight markers (kDa); l ne 5, SCR-1+2-tPA; lane 6,
SCR-1+3-tPA; lane 7, SCR-2+3-tPA; lane 9, tPA.
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Figure 2. Immunoblot of chimeric SCR-tPA constructs.
Purified chimeric SCR-tPA constructs (200 ng) were applied to 10% SDS PAGE gel
under nonreducing (A) and reducing conditions (B). Proteins were transferred to
polyvinylidene difluoride membranes and visualized using polyclonal antibodies against
tPA. Lane 1, SCR-1-tPA; lane 2, SCR-2-tPA; lane 3, SCR-3-tPA; lanes 4 and 8,
molecular weight markers (kDa); l ne 5: SCR-1+2-tPA; lane 6, SCR-1+3-tPA; lane 7,
SCR-2+3-tPA; lane 9, tPA.
Binding of protein S to immobilized chimeric SCR-tPA constructs
The interaction of chimeric SCR-tPA constructs with protein S was investigated using a
direct binding assay in which protein S was allowed to bind to immobilized chimeric SCR-
tPA constructs (Figure 3). The results are expressed as a percentage of maximum binding
(Bmax) for each construct. Apparent dissociation constants of the binding of protein S to
Figure 3. Binding of human protein S to immobilized chimeric SCR-tPA constructs.
Chimeric SCR-tPA constructs were immobilized to microtiter wells using polyclonal
antibodies against tPA. After incubation with increasing concentrations of protein S,
bound protein S was detected using peroxidase-conjugated polyclonal antibodies against
protein S. Bound protein S was expressed as a percentage of Bmax. Values are displayed
as means of three experiments ± SD. , SCR-1; r, SCR-2; ¢, SCR-3; , SCR-1+2; p,
SCR-1+3; £, SCR-2+3; á, tPA.
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chimeric SCR-tPA constructs were 10.3 nM for SCR-1, 1.9 nM for SCR-1+2 and 13.7 nM for
SCR-1+3, respectively. Protein S did not bind to SCR-2, SCR-3, SCR-2+3 or tPA. The
apparent dissociation constant for the binding of protein S to plasma C4BP was 1.7 nM,
which is identical to published values (119). This indicates that protein S has an affinity for
SCR-1+2 that is comparable with the affinity for plasma C4BP whereas the affinity of protein
S for SCR-1 and SCR-1+3 was approximately 5 times lower.
Binding of chimeric SCR-tPA constructs to immobilized protein S
A binding assay was performed in which chimeric SCR-tPA constructs were allowed to
bind to immobilized protein S. The results of the binding experiments of chimeric SCR-tPA
constructs to immobilized protein S are presented in Figure 4. Binding of each chimeric SCR-
tPA construct is expressed as a percentage of Bm x to protein S. The apparent dissociation
constants for the binding of chimeric SCR-tPA constructs to protein S are 207.4 nM for SCR-
1, 24.9 nM for SCR-1+2 and 124.0 nM for SCR-1+3, respectively. SCR-2, SCR-3, SCR-2+3
and tPA did not bind to protein S. The apparent dissociation constant for the binding of
plasma purified C4BP to protein S was 2.9 nM, which is in the range of previously published
values between 2 and 5 nM (156). This implies that in this system, SCR-1+2 has an affinity
for protein S approximately 5-10 times lower compared with plasma purified C4BP.
Figure 4. Binding of chimeric SCR-tPA constructs to immobilized human protein S.
Protein S was immobilized to microtiter wells using polyclonal antibodies. After incubation
with increasing concentrations of chimeric SCR-tPA constructs, bound chimeric SCR-tPA
constructs were detected using polyclonal antibodies against tPA. Bound chimeric SCR-
tPA constructs were expressed as percentages of Bmax. Values are displayed as means
of three experiments ± SD. , SCR-1; r, SCR-2; ¢, SCR-3; , SCR-1+2; p, SCR-1+3; £,
SCR-2+3; á, tPA.
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Stoichiometry of the interaction between protein S and SCR-tPA constructs
The stoichiometry of the interaction between protein S and the SCR-tPA constructs that
bound to protein S was analyzed using a fluid phase binding assay. Increasing concentrations
of SCR-tPA constructs were allowed to bind to protein S, after which total protein S was
immunoprecipitated using rabbit anti-protein S antibodies coupled to Sepharose beads. After
immunoprecipitation, no protein S could be detected in the supernatant using a polyclonal
protein S ELISA. Free SCR-tPA in the supernatant was determined using a polyclonal tPA
ELISA. Bound SCR-tPA was calculated by subtracting values for free SCR-tPA from the
concentrations of SCR-tPA added. Values for bound SCR-tPA were plotted against free SCR-
tPA (data not shown) and the Bmax of each SCR-tPA construct was calculated. The
stoichiometry of the interaction of protein S with each protein S-binding SCR-tPA construct is
presented in Table II as the ratio of Bmax and the protein S concentration used. The values for
Bmax/protein S displayed in Table II are presented as means of two separate experiments. One
protein S molecule was found to bind to 1.0 molecule of SCR-1, 1.0 molecule of SCR-1+2
and 1.1 molecule of SCR-1+3, respectively. These findings show that each SCR-tPA
construct that is able to bind to protein S (SCR-1, SCR-1+2 and SCR-1+3) contains one
binding site for protein S, confirming the existence of a single binding site for protein S on the
b-chain of C4BP.
Table II. Overview of apparent dissociation constants and concentrations of 50%
inhibition.
Only the chimeric SCR-tPA constructs that bound to protein S are shown. The data
presented are derived from the figures referred to in the table. The stoichiometry of the
interaction of the SCR-tPA constructs with protein S (Bmax/protein S ratios, final column)
were determined in two independent fluid phase binding assays.
Ligand
Apparent KD, binding of
protein S to immobilized
SCRs (Fig. 3)
Apparent KD, binding of
SCRs to immobilized
protein S (Fig. 4)
50% inhibition of binding
of protein S to
immobilized C4BP 
(Fig. 5)
50% inhibition of
protein S cofactor
activity (Fig. 6)
Stoichiometry
(Bmax/protein S)
SCR-1
SCR-1+2
SCR-1+3
nM
10.3
  1.9
13.7
nM
207.4
  24.9
124.0
nM
212
  22
179
nM
320
  70
210
1.0
1.0
1.1
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Competition experiments using chimeric SCR-tPA constructs for binding of protein S
to immobilized C4BP
Chimeric SCR-tPA constructs were allowed to compete with immobilized plasma purified
C4BP to bind protein S. In these experiments, purified human protein S (0.5 nM) was
preincubated with increasing concentrations of chimeric SCR-tPA constructs and then
allowed to bind to immobilized purified human C4BP. Bound protein S was expressed as a
percentage of maximum binding in the absence of chimeric SCR-tPA constructs in Figure 5.
Preincubation of protein S with SCR-1+2 resulted in inhibition of protein S binding, and a
50% inhibition of protein S binding was observed at 22 nM SCR-1+2. SCR-1 and SCR-1+3
had only a minor effect on the binding of protein S to C4BP, and a 50% inhibition of protein
S binding was observed at 212 and 179 nM, respectively. In agreement with the results of the
direct binding assays (Figures 3 and 4), SCR-2, SCR-3, SCR-2+3 and tPA did not compete
for protein S binding.
Figure 5. Competition of chimeric SCR-tPA constructs with immobilized human
C4BP for protein S binding.
C4BP was immobilized to microtiter wells using monoclonal antibodies against C4BP a-
chain. After preincubation of human protein S with chimeric SCR-tPA constructs, protein
S was allowed to bind to immobilized C4BP. Bound protein S was detected using
peroxidase-conjugated polyclonal antibodies against protein S. Bound protein S was
expressed as a percentage of maximum binding in the absence of chimeric SCR-tPA
constructs. Values are displayed as means of three experiments ± SD. , SCR-1; r,
SCR-2; ¢, SCR-3; , SCR-1+2; p, SCR-1+3; £, SCR-2+3; á, tPA.
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Protein S cofactor activity in plasma
The effect of the SCR constructs on the cofactor activity of protein S was tested by
preincubation of 20 nM protein S (final concentration) with increasing concentrations of
chimeric SCR-tPA constructs. Subsequently, C4BP- and protein S depleted plasma was
added, and the clotting time was determined in the presence of 30 nM APC. The residual
cofactor activity of protein S after preincubation with chimeric SCR-tPA constructs is shown
in Figure 6. SCR-1+2 yielded a 50% inhibition of protein S cofactor activity at a
concentration of approximately 70 nM (SCR-tPA:protein S ratio of 3.5). A 50% inhibition of
protein S cofactor activity by SCR-1 and SCR-1+3 was obtained at 320 nM SCR-1 (SCR-
tPA:protein S ratio of 16) and 210 nM SCR-1+3 (SCR-tPA:protein S ratio of 10.5),
respectively. Preincubation of protein S with SCR-2, SCR-3, SCR-2+3 or tPA had no effect
on the cofactor activity of protein S. The inhibition of protein S cofactor activity by SCR-1+2
is in concert with the competition experiments shown in Figure 5. The maximum inhibitory
effect in both experiments is accomplished at approximately 300 nM SCR-1+2. At these
concentrations, maximum binding of SCR-1+2 occurred in the direct binding assays of
chimeric SCR-tPA constructs to immobilized protein S shown in Figure 4. This suggests that
the decrease in protein S cofactor activity can be attributed to the complex formation of
protein S with SCR-1, SCR-1+2 and SCR-1+3, respectively.
Figure 6. Inhibition of protein S cofactor activity by chimeric SCR-tPA constructs.
Human protein S (final concentration 20 nM) was preincubated with chimeric SCR-tPA
constructs and added to a mixture of C4BP- and protein S depleted plasma and 30 nM
activated protein C. After the addition of 25 mM CaCl2, the clotting time was determined.
Protein S cofactor activity was expressed as percentage of maximum activity in the
absence of chimeric SCR-tPA constructs. Values are displayed as means of two
experiments. , SCR-1; r, SCR-2; ¢, SCR-3; , SCR-1+2; p, SCR-1+3; £, SCR-2+3; á,
tPA.
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Discussion
The binding site of protein S on C4BP has been localized before on the b-chain of C4BP
(127,160,197), and residues within the first NH2- erminal SCR unit were shown to be
important for the interaction between protein S and C4BP (154-156,204). In this report, the
possible role of the second and third b-c ain SCR unit in this interaction was investigated
using chimeric constructs containing b-chain SCR units fused to a modified tPA module. This
tPA module is well characterized and has been proven in previous studies to be a useful tool
to investigate the function of protein modules (198-200). The SCR units in these SCR-tPA
chimeras were recognized by several monoclonal antibodies directed against the b-chain of
C4BP (unpublished observations). The binding of protein S to the SCR-tPA constructs and
the effect on the cofactor function of protein S for activated protein C due to the interaction
with these chimeric SCR constructs were investigated.
Binding assays of chimeric SCR-tPA constructs and protein S showed thatconstruc s
containing SCR-1 bind to protein S with a stoichiometry of 1:1 (Table II), whereas constructs
lacking SCR-1 did not bind to protein S (Figures 3 and 4). These studies confirm previous
results that have localized the protein S-binding site to the NH2-terminal SCR (SCR-1) of
C4BPb (154-156,204). The binding of protein S to immobilized SCR-1+2 occurred with the
same affinity as for binding to plasma C4BP, whereas the binding of SCR-1+2 to
immobilized protein S occurred with an affinity that was approximately 5-10 times lower
compared with plasma C4BP. The reason for this discrepancy is not known.
Interestingly, constructs containing SCR-1 but lacking SCR-2 (SCR-1 and SCR-1+3) had
an affinity that was approximately 5 times lower for protein S than SCR-1+2. This was found
in the binding of protein S to immobilized SCR-tPA constructs (Figure 3) as well in the
binding of SCR-tPA constructs to immobilized protein S (Figure 4). These results were
confirmed by competition experiments in which soluble chimeric SCR-tPA constructs were
allowed to compete with immobilized C4BP for binding to protein S (Figure 5). A possible
explanation for the difference found between SCR-1 and SCR-1+2 is that SCR-2 in the latter
construct could function as a spacer, localizing SCR-1 distant from the tPA module and
thereby yielding better binding properties of this SCR module. However, such an additional
SCR unit is also present in the construct SCR-1+3 while this construct had a binding affinity
for protein S as low as SCR-1 alone. This implies that the contribution of SCR-2 in the
interaction between protein S and SCR-1+2 was specific and can not be explained by a spacer
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function alone. Instead, SCR-2 could cause a conformational change in SCR-1 that yields a
higher affinity binding of SCR-1 to protein S. Alternatively, when SCR-2 is adjacent to SCR-
1 and SCR-1 is bound to protein S, SCR-2 may bind to protein S as well, thereby yielding a
higher affinity binding of SCR-1+2 to protein S.
In previous studies using synthetic peptides, a peptide comprising b-chain SCR-1 residues
34-42 was able to completely inhibit the binding of a monoclonal antibody directed against
residues 420-434 of protein S (155), and also C4BP was found to bind to a peptide
comprising protein S residues 408-434 (169), implying that b-chain residues 34-42 bind near
residues 420-434 of protein S. In another study, a synthetic peptide comprising protein S
residues 605-614 was shown to inhibit the binding of protein S to C4BP, and in addition
C4BP was shown to bind also to this immobilized peptide (173). Int restingly, deletion
variants of protein S lacking residues 607-635 (176) and residues 583-635 (177)were shown
to have markedly reduced affinities for binding to C4BP. Peptides comprising a third region
in protein S that inhibit binding of protein S to C4BP have been found (172). It is tempting to
speculate that C4BPb SCR-1 and SCR-2 each have their own binding region within protein S.
It is known that the b-chain is highly glycosylated (128) and that the multiple carbohydrate
side chains present in the b-c ain of C4BP are not involved in the protein S binding (153). As
shown in Figures 1 and 2, the SCR-tPA chimeras are also highly glycosylated. Since the
carbohydrate side chains are not involved in the interaction between protein S and C4BP, a
possible different glycosylation of the chimeric SCR-tPA chimeras is excluded to be the cause
of the different binding affinities reported here for the interactions between the chimeric SCR-
tPA constructs and protein S.
The finding that b-chain SCR-2 is involved in the interaction of protein S with SCR-1 is
not in agreement with the results of Härdig and Dahlbäck, who found that SCR-1 of C4BPb
bound to protein S with an affinity comparable with plasma purified C4BP (156). In their
study, Härdig and Dahlbäck composed chimeras of C4BP a-chains with one, two or three of
the NH2-terminal SCR modules replaced by the -chain counterpart. Hence, next to the b-
chain SCR-1 unit in all of their constructs, an additional second NH2-terminal SCR unit from
the a chain or b-chain was present and this may explain the different results compared with
our study. It is possible that the second NH2-terminal SCR unit derived from the a-chain in
their constructs was able to exert a function comparable with SCR-2 of C4BPb, yielding the
same affinity of protein S for all of the a-chain chimeras. A possible explanation for this may
be found in the homology between the SCR units from the a-chain (125) and the b-chain
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(128). A specific sequence present in the second NH2-terminal SCR unit of both the a-chain
and the b-chain may result in an optimal folding of b-chain SCR-1 or, alternatively, may
contain sites that contribute to the binding of protein S to b-cha CR-1.
A role of the a-chains in the interaction with protein S was previously proposed in studies
by Suzuki and Nishioka (129). In their study, a COOH-terminal core fragment derived from
C4BP (Mr 160,000) was found to contain a protein S binding site, and after reduction and
carboxymethylation of the COOH-terminal fragment, a peptide of Mr 2,500 c rresponding to
Ser447-Tyr467 was identified as the protein S binding region. Possibly, this region (within the
eighth SCR unit of the a-chain) may also contain a sequence homologous to the sequence
discussed above that in combination with b-chain SCR-1 could contribute to the binding
affinity of b-chain SCR-1 with protein S. Hessing et al. (158) have identified monoclonal
antibodies directed against the a-chain that inhibited the binding of protein S to C4BP. The
inhibitory effect of these antibodies on the interaction between protein S and C4BP is most
likely to be due to steric hindrance, but does not exclude the possibility that the a-chains c n
also play a role in the interaction between C4BP and protein S.
In our activated partial thromboplastin time-based coagulation assay, SCR-1+2 had the
strongest effect in the inhibition of cofactor activity of protein S (Figure 6). Maximum
inhibition of protein S cofactor activity was accomplished at concentrations at which also
maximum binding was accomplished in the direct binding assays (Figure 4). Hence, inhibition
of protein S cofactor activity can be attributed to the complex formation between chimeric
SCR-tPA constructs and protein S. Nishioka and Suzuki (103) have shown that protein S in
complex with C4BP is still able to bind to APC, excluding the possibility that C4BP prevents
binding of protein S to APC by steric hindrance. Studies using fluorescence resonance energy
transfer have shown that protein S alters the active site location of APC closer to the
membrane surface and as a mechanism, a change in topography and/or conformation of the
active site of APC has been postulated (64). A possible mechanism for the decrease in protein
S cofactor activity due to the complex formation of protein S with C4BP could be that C4BP
prevents protein S from inducing this topographical and/or conformational change in the
active site of APC. The mechanism by which C4BP prevents this change in topography and/or
conformation could be by altering the conformation of protein S or vice versa, preventing
protein S from changing into a conformation that is necessary to express cofactor activity. In
the mechanism of inhibition of protein S cofactor activity, it is most likely that the SCR-tPA
chimeras SCR-1, SCR-1+2 and SCR-1+3 act in a way comparable with C4BP. The exact
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contribution of the SCR-tPA constructs in the decrease in cofactor activity of protein S for
APC in the inhibition of factors Va and VIIIa remains to be elucidated.
We conclude that the second NH2-terminal SCR unit of C4BPb contributes to the
interaction between protein S and the first NH2-terminal SCR-unit of C4BPb. This is the first
time that another SCR unit than b-chain SCR-1 has been shown to be involved in the
interaction of C4BP with protein S.
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C4b-binding protein (C4BP) b-chain short consensus repeat-2
specifically contributes to the interaction of C4BP with protein S
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Summary
C4b-binding protein (C4BP) regulates the complement system and the anticoagulant
activity of protein S. Protein S can bind to C4BP resulting in a decreased cofactor activity of
protein S for anticoagulant activated protein C. C4BP contains several identical a-ch ins and
a single b-chain. Each chain contains Short Consensus Repeats (SCRs). By making chimeras
of b-chain SCRs fused to tissue-type plasminogen activator (tPA chimeras), we found that b-
chain SCR-2 contributed to the interaction of b-chain SCR-1 with protein S (van de Poel
RHL, Meijers JCM and Bouma BN. J Biol Chem 1999; 274: 15144-15150). Chimeras
containing C4BP a-chains with SCR-1, SCR-1+2 or SCR-1+2+3 replaced by their b-chain
counterpart had affinities for protein S similar to C4BP (Härdig Y and Dahlbäck B. J Biol
Chem 1996; 271: 20861-20867). This was not in agreement with the finding that b-chain
SCR-2 contributed to the interaction and could be explained by the possibility that a-cha n
SCR-2 in the a-chain chimeras contributed comparable with -chain SCR-2 in the tPA
chimeras. To investigate this we constructed a tPA chimera containing b-chai  SCR-1 and a-
chain SCR-2 (b1a2). Binding studies showed that b1a2 had a lower affinity compared with
SCR-1+2, indicating that a-chain SCR-2 did not contribute to the interaction. The difference
with the a-chain chimeras may be explained by the fact that the a-chain c imeras were linked
by their C-terminal cysteines resulting in multiple binding sites in a single molecule. Thereby,
the effect of a lower affinity of each a-chain chimera may have been masked. The studies
performed here help to clarify the apparent inconsistencies in two previous reports about the
contribution of the SCR-2 domain in C4BP to protein S binding. In conclusion, b- hain SCR-
2 specifically contributes to the interaction of SCR-1 with protein S.
Introduction
C4b-binding protein (C4BP) regulates the classical pathway of complement activation
(104-108). It accelerates C2a decay from the C3-convertase (C4b2a) complex (107,113) and
promotes degradation of C4b by factor I (105-107,112). C4BP also binds to anticoagulant
vitamin K-dependent protein S in a high affinity 1:1 stoichiometric complex
(118,119,193,194). By binding of protein S to C4BP, the cofactor function of protein S for
anticoagulant activated protein C (APC) in the inactivation of coagulation factors Va and
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VIIIa is decreased (102,103). Binding of protein S to C4BP does not interfere with the
inhibition of complement activation. C4BP contains six or seven identical a-chains (Mr
70,000) and 80-85% of the C4BP molecules contain an additional single b-chain (Mr 45,000)
that binds to protein S (115,193,197). Both the a- and b-chains contain cysteine residues in
their C-terminal part that form the interchain disulfide bridges in the so-called core region of
C4BP (128). Under normal conditions approximately 60% of total protein S is in complex
with C4BP and 40% is free (130). C4BP levels can increase up to four-fold during an acute
phase response, and due to a mechanism of differential regulation of a- and b-chain
expression by which mainly the expression of a-chains increases, free protein S levels remain
stable (130).
The a- and b-chains are composed of short consensus repeats (SCRs), also called
complement control protein (CCP) modules or Sushi domains (125,128). SCRs have been
shown to have complement C3b/C4b binding properties (149) in complement regulatory
proteins such as factor H and Decay Accelerating Factor. However, SCRs have also been
found in noncomplement regulatory proteins such as b2-glycoprotein I and the b-subunit of
coagulation factor XIII in which the function of SCRs is unknown (for reviews see references
149 and 150). The a-chain of C4BP contains eight SCRs, the b-chain contains three SCRs. It
is known from previous studies that the protein S binding site is localized within the NH2-
terminal SCR unit (SCR-1) of the b-chain (153-156,205). Chimeras containing C4BP a-
chains with SCR-1, SCR-1+2 or SCR-1+2+3 replaced by their b-chain counterpart had
affinities for protein S comparable with plasma C4BP (156). In our previous study using
chimeras of b-chain SCRs fused to the NH2-terminus of a modified tissue-type plasminogen
activator (tPA chimeras, 198), we found that b-chain SCR-2 contributed to the interaction of
SCR-1 with protein S (205). The experiments using the a-c ain chimeras showed a different
effect compared with the tPA chimeras. To investigate whether -chain SCR-2 in the a-chain
chimeras contributed in a similar way as b-chain SCR-2 in the tPA chimeras to the interaction
of protein S with b-chain SCR-1, a tPA chimera was constructed containing b-ch i  SCR-1
and a-chain SCR-2 (designated b1a2). This report helps to clarify the apparent
inconsistencies in two previous reports about the contribution of SCR-2 in the C4BP to
protein S binding. It was found that the contribution to the affinity for protein S was specific
for b-chain SCR-2, since this could not be substituted by SCR-2 of the a-chain of C4BP.
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Methods
Proteins
Complement C4b-binding protein (C4BP) was immunopurified from human plasma as
described (160). Protein C was purified and activated as described previously (91). Pr tein S
was purified from prothrombin concentrates as described (201). SCR-tPA chimeras
containing b-chain SCRs were expressed and immunopurified as described in our previous
report (205).
Cloning procedure
The first NH2-terminal SCR from the b-chain (b1) and the second NH2-terminal SCR from
the a-chain (a2) of C4BP were amplified by PCR amplification using the DNA construct
containing the b/a-chain chimera designated b1a as described (156) as a template. The
oligonucleotides used for construction of the b1a2 chimera were SCR1bF2 (5' TTT AGA
TCT  GAG CAC TGT CCA GAG CTT CCT CCA GTG 3') and SCR2aR (5' T TTC TCG
AGT TTC ACA TTG TGG GAG AGG AT 3'). After amplification, the PCR product was
cleaved with BglII (boldface) and XhoI (underlined) and cloned in BglII/XhoI-cleaved
expression vector Zpl7 containing a modified tissue-type plasminogen activator (tPA, 199).
The sequence of the amplified region was confirmed by dideoxy sequencing.
Cell line and culture conditions
Transfection of baby hamster kidney cells was performed as described previously (203).
Expression of all constructs was performed in conditioned serum-free medium (UltraCHOTM,
BioWhittaker, Verviers, Belgium) and harvested medium was stored at –20 oC until needed
for further use.
Purification of recombinant proteins
Purification of chimeric SCR-tPA constructs was performed as described previously (198)
using a monoclonal antibody against tPA. Concentrations of chimeric SCR-tPA constructs
were determined using an ELISA system that determines tPA concentration (ImulyseTM tPA,
Kordia, Leiden, The Netherlands). Purified constructs were applied to 10% SDS-PAGE under
nonreducing conditions, and stained by Coommassie Brilliant Blue.
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Ligand-binding assays
The binding of protein S to immobilized SCR-tPA chimeras, binding of SCR-tPA chimeras
to immobilized protein S, stoichiometry of the interaction between protein S and b1a2 and
the competition of SCR-tPA chimeras with immobilized C4BP for protein S binding was
investigated using the same experiments as described in our previous report (205). Thes
assays were all performed in the presence of 5 mM CaCl2. Purified SCR-tPA chimeras and
protein S were immobilized using polyclonal antibodies directed against tPA and protein S,
respectively. The binding of protein S to immobilized tPA chimeras was performed with a
minor modification: purified SCR-tPA constructs at a coating concentration of 10 nM were
used instead of culture supernatant.
Clotting assay
The effect of SCR-tPA chimeras on protein S cofactor activity was performed using an
activated partial thromboplastin time (APTT)-based assay as described previously (205). P ior
to the clotting assay, protein S and the tPA chimeras were preincubated for 30 min in the
presence of 3 mM CaCl2.
Results
Expression and purification of chimeras
In order to investigate if the contribution of SCR-2 to the interaction of protein S with
SCR-1 is specific for SCR-2 from the b-c ain, a chimera was constructed containing SCR-1
from the b-chain and SCR-2 from the a-chain of C4BP fused to the NH2-terminus of a
modified tPA. Baby hamster kidney cells were transfected with the expression vector
containing the SCR-tPA chimeras. Expression levels in the medium were detected using a
tPA ELISA system and were 1-5 µg/ml after 3 days of culture. After purification of the
constructs with an immobilized monoclonal antibody against tPA, the constructs were applied
to 10% SDS-PAGE under nonreducing conditions and stained by Coommassie Brilliant Blue
(Figure 1). As seen in our previous report (205), the SCR-tPA constructs appeared as diffuse
bands which is probably caused by heterogeneous glycosylation of the SCRs and the tPA
module. The construct b1a2 migrated as a band with an estimated molecular weight of
70,000-75,000, which was slightly higher then SCR-1. In principle, one would expect the
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construct b1a2 to have a mobility approximately the same as SCR-1+2 and SCR-1+3. This
was not the case however, and is most likely due to glycosylation that is known to
considerably affect the mobility shift of proteins.
Figure 1. SDS-PAGE of SCR-tPA chimeras.
Purified tPA chimeras (1.5 mg) were applied to 10% SDS-PAGE gel under nonreducing
conditions. Proteins were visualized by Coommassie Brilliant Blue staining. L nes 1 and
6, molecular weight markers (kDa); l ne 2, SCR-1-tPA; lane 3, SCR-1+2-tPA; lane 4,
SCR-1+3-tPA; lane 5, SCR-b1a2-tPA.
Binding of protein S to immobilized chimeras
The interaction of the SCR-tPA constructs with protein S was investigated using a direct
binding assay in which protein S was allowed to bind to immobilized SCR-tPA chimeras
(Figure 2). The results were expressed as a percentage of maximum binding (B ax) for each
construct. Apparent dissociation constants of the binding of protein S to tPA chimeras were
16.9 nM for SCR-1, 2.0 nM for SCR-1+2 and 13.5 nM for SCR-1+3, respectively. These
values were similar to our previous findings with these constructs (205). The affinity for the
binding between protein S and C4BP is in the range between 2 and 5 nM (119,156). The
apparent dissociation constant for the binding of protein S to b1a2 was 10.2 nM. These
results showed that protein S had an affinity for b1a2 comparable with SCR-1 and SCR-1+3.
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Figure 2. Binding of protein S to immobilized chimeras.
SCR-tPA constructs were immobilized to microtiter wells using polyclonal antibodies
against tPA. After 2 hours of incubation with increasing concentrations of human protein
S, bound protein S was detected using peroxidase-conjugated polyclonal antibodies
against protein S. After correction for background absorbance, bound protein S was
expressed as a percentage of Bmax. Values are displayed as means (± SD) of three
separate experiments. , SCR-1; , SCR-1+2; p, SCR-1+3; £, b1a2.
Binding of chimeras to immobilized protein S
A binding assay was performed in which SCR-tPA constructs were allowed to bind to
immobilized protein S. The results of the binding experiments of SCR-tPA chimeras to
immobilized protein S are presented in Figure 3. Binding of each SCR-tPA construct was
expressed as a percentage of Bmax to protein S. The apparent dissociation constants for the
binding of tPA chimeras to protein S were 23.1 nM for SCR-1, 1.5 nM for SCR-1+2 and 14.0
nM for SCR-1+3, respectively. These apparent dissociation constants were somewhat lower
as previously reported (205), but showed the same effect of b- hain SCR-2 in the interaction
of protein S with SCR-1. The reason for the discrepancy of the apparent dissociation constants
for SCR-1, SCR-1+2 and SCR-1+3 compared with our previous study (205) is unknown but it
did not affect the conclusion that b-c in SCR-2 contributed to the interaction of protein S
with b-chain SCR-1. The apparent dissociation constant for the binding of b1a2 to pr tein S
was 14.0 nM. These results showed that b1a2 had an affinity for protein S comparable with
SCR-1 and SCR-1+3.
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Figure 3. Binding of chimeras to immobilized protein S.
Human protein S was immobilized to microtiter wells using polyclonal antibodies. After 2
hours of incubation with increasing concentrations of SCR-tPA chimeras, bound chimeras
were detected using polyclonal antibodies against tPA. After correction for background
absorbance, bound constructs were expressed as percentages of Bmax. Values are
displayed as means (± SD) of three separate experiments. , SCR-1; , SCR-1+2; p,
SCR-1+3; £, b1a2.
Stoichiometry of the interaction between protein S and b1a2
The stoichiometry of the interaction between protein S and b1a2 was analyzed using a
fluid phase binding assay as described (205). A value of 1.3 was found for the ratio of
maximum binding of b1a2 and the protein S concentration used in this fluid phase binding
assay (mean of two separate determinations), which is in agreement with the existence of a
single protein S binding site on b1a2. This was also found for SCR-1, SCR-1+2 and SCR-
1+3 (205).
Competition of chimeras with immobilized C4BP for protein S binding
SCR-tPA constructs were allowed to compete with immobilized plasma purified C4BP to
bind to protein S. Purified human protein S (0.5 nM) was preincubated with increasing
concentrations of SCR-tPA constructs and then allowed to bind to immobilized purified
human C4BP. Bound protein S was expressed as a percentage of maximum binding in the
absence of SCR-tPA chimeras in Figure 4. Preincubation of protein S with SCR-1, SCR-1+2,
SCR-1+3 or b1a2 resulted in an inhibition of protein S binding, and a 50% inhibition of
protein S binding was observed at 185 nM SCR-1, 12 nM SCR-1+2, 107 nM SCR-1+3 and 85
nM b1a2, respectively. Thus, higher concentrations of b1a2 were necessary to yield a 50%
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inhibition of protein S binding to immobilized C4BP compared with SCR-1+2. The
concentrations of SCR-1, SCR-1+2 and SCR-1+3 at which a 50% inhibition of binding of
protein S occurred were comparable with the concentrations found in our previous report
(205). As a control, tPA alone did not inhibit the binding of protein S to C4BP.
Figure 4. Competition of chimeras with immobilized C4BP for protein S binding.
C4BP was immobilized to microtiter wells using monoclonal antibodies against the C4BP
a-chain. After 1 hour of preincubation of human protein S with SCR-tPA chimeras, protein
S was allowed to bind to immobilized C4BP for 2 hours. Bound protein S was detected
using peroxidase-conjugated polyclonal antibodies against protein S. After correction for
background absorbance, bound protein S was expressed as a percentage of maximum
binding in the absence of SCR-tPA chimeras. Values are displayed as means (± SD) of
three separate experiments. , SCR-1; , SCR-1+2; p, SCR-1+3; £, b1a2; á, tPA.
Protein S cofactor activity in plasma
The effect of the SCRs on the cofactor activity of protein S was tested by preincubation of
20 nM protein S (final concentration) with increasing concentrations of SCR-tPA constructs.
Subsequently, C4BP- and protein S depleted plasma was added and the clotting time was
determined in the presence of 30 nM APC. The residual cofactor activity of protein S after
preincubation with SCR-tPA chimeras is shown in Figure 5. SCR-1+2 yielded a 50%
inhibition of protein S cofactor activity at a concentration of approximately 20 nM. A 50%
inhibition of protein S cofactor activity by b1a2 was observed at higher concentrations,
approximately 138 nM. As a comparison, the inhibition of protein S cofactor activity by SCR-
1 and SCR-1+3 is also displayed in Figure 5. Concentrations higher than 175 nM SCR-1 and
SCR-1+3 were necessary to yield a 50% inhibition of protein S cofactor activity. The values
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for SCR-1, SCR-1+2 and SCR-1+3 that were necessary to yield a 50% inhibition of protein S
cofactor activity were in agreement with our previous report (205). Like SCR-1 and SCR-
1+3, b1a2 was a less potent inhibitor of the protein S cofactor activity compared with SCR-
1+2.
Figure 5. Protein S cofactor activity in plasma.
Human protein S (final concentration 20 nM) was preincubated for 30 min with SCR-tPA
chimeras and added to a mixture of C4BP- and protein S-depleted plasma and 30 nM
APC. After addition of 25 mM CaCl2, the clotting time was determined. Protein S cofactor
activity was expressed as percentage of maximum activity in the absence of SCR-tPA
constructs. Values are displayed as means of at least two experiments. , SCR-1; ,
SCR-1+2; p, SCR-1+3; £, b1a2.
Discussion
Protein S binds to the b-chain of C4BP (127,160,197), and the binding site has been
localized to residues within the first NH2-terminal SCR module of the b-chain (154-156,204).
Two studies were previously performed in order to investigate the contribution of other C4BP
SCR modules to the interaction of C4BP with protein S (156,205). Using tPA chimeras
containing b-chain SCRs, we found that SCR-2 contributed to the interaction of protein S
with SCR-1 (205). The interaction of protein S with the b-chain SCRs has also been studied
using C4BP a-chain chimeras in which the NH2-terminal SCR modules 1, 1+2 or 1+2+3 were
replaced by their b-chain counterpart (156). Using the a-chain chimeras, it was found that the
binding affinities of all chimeras were comparable with plasma C4BP and hence there was no
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contributional role ascribed to b-chain SCR-2. Since we concluded from the study using the
tPA chimeras that b-chain SCR-2 contributed to the interaction (205), the findings in these
two separate studies were not in agreement. This difference could be explained by the
possibility that in the a-chain chimeras, -chain SCR-2 contributed to the interaction of b-
chain SCR-1 with protein S as well. Possibly, a-chain SCR-2 could exert a similar function
like b-chain SCR-2 implying that the contributional role for b-chain SCR-2 as described (205)
was not specific for b-chain SCR-2. To answer this question, we constructed a tPA chimera
containing b-chain SCR-1 (b1) and a-chain SCR-2 (a2). With this construct (designated
b1a2) we performed the same experiments as described in our previous report (205). The
binding of protein S to immobilized SCRs and the binding of SCRs to immobilized protein S
were investigated, and competition experiments were performed in which the SCRs were
allowed to compete with immobilized C4BP for protein S binding. Finally, the effect of the
tPA chimeras on the cofactor activity of protein S for APC was investigated.
The binding of protein S to immobilized SCRs (Figure 2) occurred in a 1:1 stoichiometry
with an affinity for b1a2 that was comparable with SCR-1 and SCR-1+3 while protein S
bound to immobilized SCR-1+2 with a stronger affinity that was comparable with C4BP. The
apparent dissociation constants for SCR-1, SCR-1+3 and SCR-1+2 were similar to the values
described previously (205). The affinity of the binding of b1a2 to immobilized protein S
(Figure 3) was also comparable with SCR-1 and SCR-1+3 while SCR-1+2 bound to
immobilized protein S with a stronger affinity that was comparable with C4BP. The apparent
dissociation constants found for SCR-1, SCR-1+3 and SCR-1+2 were lower as previously
reported (205), but showed the same contributional effect of b-chain SCR-2 in the interaction
of protein S with SCR-1. The reason for the discrepancy of the apparent dissociation constants
for SCR-1, SCR-1+2 and SCR-1+3 compared with our previous study (205) is unknown. To
confirm the results of the direct binding assays, competition experiments were performed in
which the SCRs were allowed to compete with immobilized C4BP for protein S binding
(Figure 4). The binding of protein S to immobilized C4BP was inhibited by b1a2 at a
concentration comparable with SCR-1 and SCR-1+3, while SCR-1+2 was a more potent
inhibitor. This was in agreement with our previous study (205) an  was also shown in the
APTT-based assay that measures protein S cofactor activity in which the effect of the SCRs
on the cofactor activity of protein S was investigated (Figure 5). In agreement with our
previous study (205), SCR-1+2 was a strong inhibitor of protein S cofactor activity while
SCR-1 and SCR-1+3 were less potent inhibitors, comparable with b1a2.
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The results of the direct binding assays, the competition experiments and the studies on the
effect of the SCRs on the cofactor activity of protein S clearly showed that b1a2 had an
affinity for protein S that was comparable with SCR-1 and SCR-1+3, while SCR-1+2 had a
stronger affinity. Apparently, SCR-2 derived from the a-chain in the construct b1a2 did not
contribute to the interaction of b-chain SCR-1 with protein S. Thus, the additional effect of b-
chain SCR-2 shown in our previous report using the tPA chimeras (205) and lso found in this
report appeared to be specific for the b-chain since a-chain SCR-2 was not able to contribute
to the interaction of b1a2 with protein S. The difference found with the a-c ain chimeras
may be explained by the fact that the a-chain chimeras were polymeric molecules containing
6-7 subunits. The N-terminus of each subunit contained the SCR(s) derived from the b-chain,
and two cysteines were present in the C-terminus that linked the subunits together in a single
molecule. By combining multiple (6-7) binding sites for protein S in a single molecule, the
effect of a lower binding affinity of each individual a-chain chimera that had SCR-1 replaced
by the b-chain counterpart may have been masked (156).
We conclude that the second NH2-terminal SCR unit of the C4BP b-chain contributes
specifically to the interaction between protein S and the first NH2- erm nal SCR unit of the b-
chain. This function has been found in our previous study (205) and in this study we showed
that this function is specific for b-chain SCR-2.
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Summary
Activated protein C (APC) is an important regulator of the coagulation cascade by
inactivating coagulation factors Va and VIIIa. In the degradation of factors Va and VIIIa,
protein S serves as a cofactor to APC. Protein S can bind to C4b-binding protein (C4BP), a
regulator of the complement system. When protein S is bound to C4BP, its cofactor activity to
APC in plasma is lost. By modulating free protein S levels, C4BP is an important regulator of
protein S cofactor activity. In the inactivation of factor VIIIa, protein S and factor V can act as
synergistic cofactors to APC. We investigated the effect of C4BP on both the factor V-
independent cofactor activity of protein S and the synergistic effect of factor V on the cofactor
activity of protein S in the inactivation of factor VIIIa using a purified system. Protein S
increased the APC-mediated degradation of factor VIIIa to 60% and in synergy with protein
S, factor V at equimolar concentrations increased this effect further to 90%. The protein
S/factor V synergistic effect was inhibited by preincubation of protein S and factor V with a
four-fold molar excess of C4BP. However, preincubation of protein S with C4BP did not
inhibit the factor V-independent protein S cofactor activity to APC in the purified system
whereas it inhibited the cofactor activity in plasma. We conclude that C4BP-bound protein S
retains its cofactor activity to APC in the degradation of factor VIIIa.
Introduction
The blood coagulation cascade is regulated by the anticoagulant protein C pathway
(39,206). Protein C is activated by the thrombin-thrombomodulin complex on the endothelial
cell surface (207) and activated protein C (APC) inactivates coagulation factors V(a)
(39,40,208) and VIII(a) (41,209,210). In the degradation of factors Va and VIIIa, protein S
serves as a cofactor to APC (48,49,51). Protein S is a vitamin K-dependent protein with high
affinity for negatively charged phospholipids. Cofactor activity of protein S is expressed by
the formation of a membrane-bound 1:1 stoichiometric complex with APC after which protein
S alters the active site location of APC (64). In addition to acting as a cofactor to APC,
protein S also has an anticoagulant activity that is independent of APC (52,55,57). The
relevance of protein S is shown by the increased risk for venous thrombosis in patients with
decreased levels of protein S (101,211). In synergy with protein S, factor V also has
anticoagulant activity, functioning as a cofactor to APC in the degradation of factor VIIIa
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(81,82). The cofactor activity of protein S to APC is abrogated by binding of protein S to
C4b-binding protein (C4BP), a regulator of the complement cascade system (102,103). So far,
the effect of C4BP on the protein S cofactor activity to APC has only been studied in systems
monitoring factor Va inactivation and in clotting assays measuring the overall cofactor
activity of protein S in plasma (84,102,103). In this study, we investigated the cofactor
activity of protein S and its synergistic cofactor factor V in the APC-mediated inactivation of
factor VIIIa. The effects of C4BP on these two synergistic cofactors were investigated using a
purified system that measures factor VIIIa activity. We report that binding of C4BP to protein
S does not abrogate the cofactor activity of protein S to APC in the inactivation of factor
VIIIa whereas the protein S/factor V-mediated synergistic effect in the factor VIIIa
inactivation was inhibited by complexation of protein S to C4BP.
Methods
Proteins
C4BP was immunopurified from human plasma as described by Hessing et al. (160).
Protein S was purified from prothrombin concentrates as described by Hackeng et al. (201). A
chimera containing C4BP b-chain (C4BPb) short consensus repeat (SCR)-1 and SCR-2 fused
to tissue-type plasminogen activator (SCR-1+2) was constructed, expressed and purified as
described before (205). Purified recombinant human factor VIII was a generous gift from Dr.
D. Pittman (Genetics Institute, Cambridge, MA, USA). Purified human a-thrombi , protein
C, protein C activator purified from Agkistrodon contortrix contortrix (ACC) and anti-ACC
polyclonal antibody were kindly provided by Dr. W. Kisiel (Department of Pathology,
University of New Mexico, Albuquerque, NM, USA). Protein C was activated by ACC after
which ACC was removed using anti-ACC polyclonal antibody as described previously (212).
Recombinant desulphato-hirudin was a gift from Dr. R. B. Wallis (Ciba-Geigy
Pharmaceuticals, Hornsham, UK). Monoclonal antibody CLB-PS13 was a generous gift from
Dr. J. A. van Mourik (Central Laboratory of the Netherlands Red Cross Blood Transfusion
Services, Amsterdam, The Netherlands).
Preparation of phospholipid vesicles
Phospholipid vesicles containing 20% phosphatidylserine, 40% phosphatidylcholine and
40% phosphatidylethanolamine were prepared as described by van Wijnen et al. (213).
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Activation of factor VIII
Due to the instability of activated factor VIII, activation of recombinant human factor VIII
(15 nM) was performed before each experiment by a-thrombin (0.6 units/ml) at room
temperature in Tris-buffered saline (TBS; 50 mM Tris-HCl, pH 7.4, 150 mM NaCl)
containing 0.3% (w/v) bovine serum albumin (BSA) and 3 mM CaCl2. Maximum activation
of factor VIII was achieved after 3 minutes as measured by a one-stage clotting assay using
factor VIII deficient plasma. Hirudin (70 units/ml) was added to stop the activation. Factor
VIIIa remained stable for at least 60 minutes at 37 oC and was stored for no longer than 45
minutes on ice before use.
Preincubation of C4BP, C4BPb SCR-1+2, CLB-PS13, protein S, factor V
All preincubations were performed for 30 minutes at 37 oC in TBS containing 0.3% BSA
and 3 mM CaCl2.
Inactivation of factor VIIIa by APC and determination of residual factor VIIIa
activity
Activated recombinant human factor VIII (30 pM) was incubated with APC (3 nM) for 3
minutes at 37 oC in TBS containing 0.3% BSA, 1 mM phospholipid vesicles and 3 mM CaCl2.
After inactivation, 20 ml aliquots were taken from the inactivation mixture and factor VIIIa
activity was immediately determined from the rate of factors VIIIa-IXa catalyzed factor X
activation in 100 ml mixtures using the factor VIII Coatest (Nodia-Chromogenix, Amsterdam,
The Netherlands). The rate of factor X activation was proportional to the amount of factor
VIIIa.
Protein S cofactor activity in plasma
Protein S cofactor activity was determined with an activated partial thromboplastin time
(APTT)-based clotting assay using a KC-10A coagulometer (Amelung, Lemgo, Germany) as
described in our previous report (205). For this assay, plasma deficient in both protein S and
C4BP was prepared by immunoadsorption as described previously (57).
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Results
Inactivation of factor VIIIa by APC
Recombinant human factor VIII was activated by a-thrombin after which a-thrombin was
neutralized with hirudin. Factor VIIIa was added to a mixture containing purified factors IXa,
X, phospholipid and calcium chloride to monitor factor VIIIa activity. Increasing
concentrations between 0 and 200 pM factor VIIIa yielded a linear increase in the rate of
factor X activation in this purified system (not shown). In order to investigate optimal
inactivating conditions, factor VIIIa was inactivated in time by different concentrations of
APC in Figure 1. The residual factor VIIIa activity after inactivation by APC was determined
and expressed as a percentage of activity in the absence of APC. Increasing concentrations of
APC resulted in a decrease in factor VIIIa activity that was time-dependent.
Figure 1. Inactivation of factor VIIIa by APC.
Recombinant human factor VIIIa (30 pM) was incubated with 0-5 nM APC in the presence
of 1 mM phospholipid vesicles and 3 mM CaCl2 at 37 
oC during indicated time periods.
After inactivation, the residual factor VIIIa activity was determined as described in the
Methods section. , no APC; , 2 nM APC; £, 3 nM APC; ¢, 5 nM APC. (Final
concentrations in the factor VIIIa inactivation mixture). Results are expressed as a
percentage of factor VIIIa activity in the absence of APC. Values are displayed as means
of three separate experiments ± SD.
Effect of protein S or C4BP on the APC-catalyzed inactivation of factor VIIIa
Factor VIIIa was incubated for 3 minutes with increasing concentrations of protein S or
C4BP in the absence or presence of APC (Figure 2). Inactivation of factor VIIIa with APC
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alone resulted in a 30-40% reduction of factor VIIIa activity, and C4BP had no effect in the
APC-catalyzed degradation of factor VIIIa. C4BP had also no effect on the factor VIIIa
activity in the absence of APC. Addition of increasing concentrations of protein S in the
presence of APC resulted in a dose-dependent decrease of factor VIIIa activity. Maximum
inhibition of factor VIIIa activity was obtained at 10 nM protein S, yielding a residual factor
VIIIa activity of approximately 15%. Protein S concentrations higher than 10 nM did not
result in further inhibition of factor VIIIa activity. Protein S in the absence of APC did not
show any effect, indicating that in the purified system only the APC-dependent (cofactor)
activity of protein S was determined.
Figure 2. Effect of protein S or C4BP on the APC-catalyzed inactivation of
factor VIIIa.
Recombinant human factor VIIIa (30 pM) was incubated with 1 mM phospholipid vesicles,
3 mM CaCl2, 0-20 nM protein S (, ) or 0-20 nM C4BP (£, ¢) in the absence (open
symbols) or presence (closed symbols) of 3 nM APC at 37 oC. After 3 minutes the
residual factor VIIIa activity was determined as described in the Methods section. Results
are expressed as a percentage of factor VIIIa activity in the absence of APC. Values are
displayed as means of three separate experiments ± SD.
Effect of C4BP on the cofactor activity of protein S to APC in the inactivation of
factor VIIIa
To investigate the effect of C4BP on the cofactor activity of protein S to APC in the
degradation of factor VIIIa, protein S was preincubated with increasing concentrations of
C4BP before addition to the inactivation mixture (Figure 3A). Based on the results shown in
Figure 2, a concentration of 5 nM protein S (final concentration in the factor VIIIa
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inactivation mixture) was used. Protein S decreased factor VIIIa activity from 100% (in the
presence of APC) to approximately 40%. Increasing concentrations of C4BP had no effect on
the protein S cofactor activity. Even an eight-fold molar excess of C4BP over protein S did
not affect the cofactor activity of protein S to APC in the inactivation of factor VIIIa, and
similar results were obtained using the protein S-binding region of the C4BP b-chain, SCR-
1+2 (Figure 3B). Protein S-C4BP complexes were formed in the preincubation time as
confirmed by an ELISA that measures protein S-C4BP complexes (not shown).
Figure 3. Effect of C4BP, C4BPb SCR-1+2 or CLB-PS13 on the cofactor activity of
protein S to APC in the inactivation of factor VIIIa.
C4BP (A), C4BPb SCR-1+2 (B) or CLB-PS13 (C) was preincubated in the absence (open
symbols) or presence of protein S (5 nM, closed symbols) during 30 minutes at 37 oC.
Preincubation mixtures were added to recombinant human factor VIIIa (30 pM), 1 mM
phospholipid vesicles, 3 mM CaCl2 and 3 nM APC. After inactivation during 3 minutes at
37 oC, the residual factor VIIIa activity was determined as described in the Methods
section. Results are expressed as a percentage of factor VIIIa activity in the presence of
APC. Values are displayed as means of three separate experiments ± SD.
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The possibility that factor VIIIa was inactivated by another process than proteolytic cleavage
by APC in the presence of protein S and C4BP was excluded in the following control
experiment. Preincubation of protein S with monoclonal antibody CLB-PS13 that is known to
inhibit the cofactor activity of protein S prevented the inactivation of factor VIIIa by APC
almost completely (Figure 3C). Also, C4BP, SCR-1+2 or CLB-PS13 in the absence of protein
S had no effect on the factor VIIIa activity.
Effect of C4BP on the cofactor activity of protein S to APC in plasma
To confirm that C4BP inhibited the protein S cofactor activity in plasma, an APTT-based
clotting assay was performed. In this assay using plasma deficient in both protein S and
C4BP, protein S showed a dose-dependent prolongation of the clotting time in the presence of
APC (Figure 4A). Preincubation of protein S (20 nM) with C4BP resulted in an inhibition of
protein S cofactor activity in plasma (Figure 4B), and a nearly complete inhibition of cofactor
activity was obtained at a two-fold molar excess of C4BP over protein S. In addition, these
results again confirmed that protein S-C4BP complexes were formed during the preincubation
period. Using the same assay, preincubation of protein S with C4BPb SCR-1+2 also resulted
in inhibition of protein S cofactor activity in plasma (205).
Figure 4. Effect of C4BP on the cofactor activity of protein S to APC in plasma.
(A) Protein S (final concentration 0-30 nM) was added to a mixture of C4BP- and protein
S-depleted plasma and 30 nM APC. After recalcification, the clotting time was
determined. Values are displayed as means of two separate determinations. (B) Effect of
preincubation of 20 nM protein S with 0-80 nM C4BP (final concentrations in the clotting
assay) during 30 minutes at 37 oC on the protein S cofactor activity to APC. Protein S
cofactor activity was expressed as a percentage of maximum activity in the absence of
C4BP. Values are displayed as means of three separate experiments ± SD.
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Effect of C4BP on the synergistic activity of cofactors protein S and factor V in the
APC-mediated inactivation of factor VIIIa
To investigate the effect of C4BP on the synergistic activity of cofactors protein S and
factor V in the degradation of VIIIa, protein S, factor V and C4BP were preincubated and
added to the factor VIIIa inactivation mixture after which residual factor VIIIa activity was
determined. Protein S together with factor V further increased the 60% inhibition of factor
VIIIa activity achieved by protein S alone to approximately 90% inhibition of factor VIIIa
activity, resulting in a 10% residual activity (Figure 5). C4BP at a concentration of 20 nM
inhibited the synergistic action of factor V and protein S, increasing the residual factor VIIIa
activity to 40%.
Figure 5. Effect of C4BP on the synergistic activity of cofactors protein S and factor
V in the APC-mediated inactivation of factor VIIIa.
C4BP was preincubated with 0-5 nM factor V in the absence or presence of protein S
during 30 minutes at 37 oC. Preincubation mixtures were added to recombinant human
factor VIIIa (30 pM), 1 mM phospholipid vesicles, 3 mM CaCl2 and 3 nM APC. After
inactivation during 3 minutes at 37 oC, the residual factor VIIIa activity was determined as
described in the Methods section. , 5 nM protein S in the absence of C4BP; , 5 nM
protein S in the presence of 20 nM C4BP; £, 20 nM C4BP in the absence of protein S.
Results are expressed as a percentage of factor VIIIa activity in the presence of APC.
Values are displayed as means of three separate experiments ± SD.
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Discussion
APC is an important regulator of the coagulation cascade by inactivating coagulation
factors Va and VIIIa (39-41,208-210). In the inactivation of factors Va and VIIIa, protein S
serves as a cofactor to APC (48,49,51). Protein S expresses its cofactor activity by promoting
the binding of APC to phospholipid surfaces and relocating its active site (64). In synergy
with protein S, factor V also acts as a cofactor to APC in the inactivation of factor VIIIa
(81,82). When protein S is bound to C4BP, both the factor V-independent cofactor activity
(102,103) and the synergistic activity of cofactors protein S and factor V is inhibited (84).
Binding of protein S to C4BP involves several regions within the sex hormone binding
globulin (SHBG)-like domain of protein S (169,172,173,176,177). C4BP consists of several
identical a-chains and a single b-chain that are composed of SCRs. The binding site of
protein S on C4BP is localized within C4BPb SCR-1 (154-156), and SCR-2 contributes to the
interaction between protein S and SCR-1 (205).
APC-mediated inactivation of factor VIIIa occurs by proteolytic degradation at several
sites within the heavy chain of factor VIII(a) (78,79. APC cleavage sites within factor VIIIa
involve residues Arg336, Arg562 and probably also Arg740. The cleavages at Arg336 and Arg562
are considered to be important in the degradation of factor VIII(a) by APC (78-80). The APC-
mediated cleavage at the Arg562 site occurs rapidly and correlates best with inactivation of
factor VIIIa (79), and cleavage at the Arg336 site occurs slowly. Inactivation of factor VIII(a)
by APC is modulated by at least four factors. First, von Willebrand factor protects factor VIII
against degradation by APC (87,91,92). Second, factor IX(a) protects factors VIII and VIIIa
against APC-mediated cleavage at Arg562 by binding to this site (87,88). In addition, factor
IXa has been shown to activate factor VIII (214) and to inactivate factor VIII(a) by cleaving
the Arg336 site (89,90). Third, protein S abolishes the factor IXa-mediated protection of the
Arg562 cleavage site by specifically accelerating cleavage at the Arg562si e (88). Fourth, factor
V acts in synergy with protein S as a cofactor to APC in the inactivation of factor VIIIa
(81,82). The synergistic activity with protein S is specific for factor V since activated factor V
does not express this synergistic cofactor activity (81,83,215,216), although Lu et al. (210)
found that the APC cofactor activity is retained in thrombin-cleaved factor V. In addition,
factor V with the R506Q mutation (factor VR506Q or factor VLeiden) that is resistant to APC
cleavage at the 506 site, has less anticoagulant activity (84,85). For factor V to act as an
anticoagulant cofactor, the C-terminal region of the factor V B-domain is crucial (215) and
APC cleavage at the Arg506 site is required (210,216), although it remains possible that factor
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VR506Q has an impaired cofactor activity to APC due to conformational changes. Protein
S/factor V synergistic cofactor activity involves binding between the two proteins (217,218),
and occurs via the SHBG-loop of protein S (219). C4BP inhibits the binding of protein S to
factors V and Va (57) and this may contribute to the inhibition of protein S cofactor activity in
the APC-mediated inactivation of factor Va (102) nd the protein S/factor V-mediated
synergistic inhibition of factor VIIIa activity (84). By binding to protein S, C4BP regulates
protein S cofactor activity. So far, the effect of C4BP on the cofactor activity of protein S has
only been studied in systems that measure factor Va inactivation or in plasma systems that
determine total protein S cofactor activity (84,102,103). In this report, the effect of C4BP on
the cofactor activity of synergistic cofactors protein S and factor V in the APC-mediated
inactivation of factor VIIIa was studied.
In the purified system used, addition of 5 nM protein S resulted in an inhibition of 60% of
factor VIIIa activity in the presence of 3 nM APC (Figures 2 and 3). Preincubation of protein
S with an eight-fold molar excess of C4BP over protein S did not inhibit the cofactor activity
of protein S (Figure 3A), while during the preincubation period protein S-C4BP complexes
were formed as confirmed by an ELISA that measures protein S-C4BP complexes (not
shown). The lack of ability to abrogate the protein S cofactor activity was confirmed by the
same experiments using a chimera containing the binding region for protein S on C4BPb,
SCR-1+2 (Figure 3B). In contrast to C4BP and C4BPb S R-1+2, preincubation of protein S
with CLB-PS13 inhibited protein S cofactor activity (Figure 3C), excluding the possibility
that factor VIIIa was inactivated by another process than proteolytic cleavage by APC in the
presence of protein S and C4BP. Binding of C4BP to protein S is known to inhibit the
cofactor activity in the APC-mediated inactivation of factor Va (102). Interestingly, we could
demonstrate that the same preparation of C4BP that did not inhibit the cofactor activity of
protein S to APC in the degradation of factor VIIIa did inhibit the protein S cofactor activity
in the APC-mediated factor Va inactivation (chapter five). The mechanism by which C4BP-
bound protein S loses its cofactor activity towards the factor Va inactivation but retains its
cofactor activity towards the factor VIIIa inactivation is unclear. Protein S binds to factor VIII
and C4BP does not inhibit this interaction (54,190) and this may explain why C4BP-bound
protein S is still able to act as a cofactor to APC in the degradation of factor VIIIa.
In synergy with protein S, factor V can increase the APC-mediated inactivation of factor
VIIIa (81,82). Addition of an equimolar amount of factor V and protein S in our purified
system resulted in an extra inhibition of factor VIIIa activity compared with protein S alone
(Figure 5). In contrast to the cofactor activity of protein S that is independent of factor V,
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C4BP inhibited the protein S/factor V-mediated synergistic effect (Figure 5). Similar results
were obtained using C4BPb SCR-1+2, although three-fold higher concentrations of SCR-1+2
compared with C4BP were required to obtain the same inhibition of protein S/factor V-
mediated synergistic effect (not shown). Higher concentrations of tPA chimeras containing
C4BPb SCR-1 without SCR-2 ( 05) were needed to inhibit the protein S/factor V-mediated
synergistic effect due to their lower binding affinity for protein S compared with SCR-1+2
(not shown). Protein S binds to factor V via the SHBG-loop (217,219), and this is also the
binding region for C4BP (169,172,173,176,177). C4BP inhibits the binding of protein S to
factor V (57) and this may cause the inhibition of the protein S/factor V synergistic cofactor
activity by C4BP in the factor VIIIa inhibition. To our knowledge, the effect of C4BP on the
protein S/factor V synergistic cofactor activity has only been shown by Váradi et al.(84). Our
study confirms this inhibition of the protein S/factor V synergistic effect by C4BP.
Protein S cofactor activity was also measured in an APTT-based clotting assay (Figure
4B). In contrast to the results obtained using the purified system, the cofactor activity of
protein S was completely inhibited by C4BP and by chimeras containing the SCR units that
comprise C4BPb (205). In the APTT-based assay the overall cofactor effect of protein S to
APC in the degradation of both coagulation factors VIIIa (in synergy with factor V) and Va in
plasma is monitored. This suggests that inactivation of factor VIIIa does not take place in the
APTT-based assay in the presence of C4BP despite the fact that C4BP had no effect on the
cofactor activity of protein S to APC in the inactivation of factor VIIIa in the purified system.
Alternatively, the APTT-based assay might not be sensitive enough to detect the inactivation
of factor VIIIa.
The factor V-dependent synergistic effect in the inactivation of factor VIIIa was abrogated
by C4BP in the purified system (Figure 5). The importance of the protein S/factor V
synergistic effect in plasma was recently demonstrated using protein S variants that either
lacked the SHBH-loop (213) or in which the SHBG-loop was replaced by a homologous
domain (219). Both variants had a normal (factor V-independent) cofactor activity in purified
systems but a decreased cofactor activity in plasma compared with wild type protein S. The
decreased cofactor activity in plasma could be explained by the absence of synergistic
cofactor activity with factor V of these protein S variants in the inactivation of factor VIIIa
(219). These results and the observations described here therefore suggest that in the APTT-
based assay the protein S/factor V synergistic cofactor effect to APC and not the factor V-
independent cofactor activity of protein S is crucial for the inactivation of factor VIIIa. This
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explains the effect of C4BP on the cofactor activity of protein S in plasma (Figure 4B). A
similar situation is observed in the APC resistance test that is used to detect factor VR506Q in
plasma. In this test, addition of APC results in a prolonged clotting time in normal pooled
plasma whereas the clotting time in factor VR506Q plasma is only marginally effected due to
the decreased APC-mediated degradation of activated factor VR506Q nd the decreased
synergistic activity of factor VR506Q with protein S in the inactivation of factor VIIIa. This also
indicates that factor VIIIa inactivation by APC does not occur or is not detected in APTT-
based clotting assays.
Our study shows that C4BP does not inhibit protein S cofactor activity in the APC-
mediated inactivation of factor VIIIa, while it does inhibit the protein S/factor V-mediated
synergistic cofactor effect. In addition, these results indicate that in plasma, inactivation of
factor VIIIa either does not occur or is not detected in APTT-based clotting assays or
alternatively, that the factor V-independent protein S cofactor activity in the factor VIIIa
inactivation is of no significant importance in the APC-mediated inhibition of coagulation.
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Summary
In coagulation, activated factor V (Va) is a cofactor to activated factor X by accelerating
the thrombin formation by several orders of magnitude. Factor Va activity is regulated by
activated protein C (APC)-mediated cleavage at Arg306, Arg506 and Arg679. Cleavages at
Arg306 and Arg506 correlate with loss of cofactor activity of factor Va. Cleavage at Arg506
occurs rapidly and results in an intermediate form with a cofactor activity of approximately
60% compared with non-cleaved factor Va, whereas cleavage at Arg306 occurs slowly and
results in total inactivation of factor Va. Protein S is a cofactor to APC, specifically
accelerating cleavage at Arg306. Cofactor activity of protein S to APC is inhibited by binding
of protein S to the b-chain of C4b-binding protein (C4BP), a regulator of the complement
system. Using a purified system that measures factor Va activity, we investigated the effect of
C4BP on the APC-mediated inactivation of factor Va in the absence and presence of protein
S. In the system used, APC decreased factor Va activity to 50%, and addition of protein S
further decreased this activity to 20%. Preincubation of protein S with C4BP resulted in a
total abrogation of protein S cofactor activity. In addition, C4BP protected factor Va from
inactivation in both the absence and presence of protein S. In the absence of protein S, the
protective effect was prevented by a monoclonal antibody directed against the a-ch in of
C4BP. A recombinant C4BP that consisted of only a-chains (rC4BPa) also protected factor
Va from inactivation in the absence of protein S. In the presence of protein S, the rC4BPa-
mediated protection of factor Va was decreased because of the absence of the protein S-
binding b-chain in rC4BPa. A truncated C4BP b-chain (SCR-1+2) inhibited the protein S
cofactor activity, but did not protect factor Va from protein S-independent inactivation by
APC. Similar results were obtained using a monoclonal antibody against protein S (CLB-
PS13). In addition, CLB-PS13 had no effect on the C4BP-mediated protection of factor Va in
the absence of protein S and thus, the possibility that the C4BP-mediated effect was caused by
a contamination with traces of protein S was excluded. In conclusion, C4BP protects factor
Va from APC-mediated cleavage in a protein S-independent way mediated via the a-chains of
C4BP.
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Introduction
Activated factor V (Va) is a cofactor to activated factor X (Xa) in the prothrombin
activating (prothrombinase) complex (see references 9 and 25 for review). Factor Va
accelerates the factor Xa-catalyzed conversion of prothrombin to thrombin on negatively
charged phospholipids by several orders of magnitude. In a similar mechanism, activated
factor VIII (VIIIa) is responsible for accelerating the activated factor IX-catalyzed activation
of factor X on negatively charged phospholipids (220). Cofactor activity of factors Va and
VIIIa can be inhibited by activated protein C (APC)-mediated cleavage of the heavy chain of
these cofactors (39-41). APC cleavage sites in the factor Va heavy chain involve residues
Arg306, Arg506 and Arg679 (65). Cleavage at Arg306 and Arg506 correlate with loss of cofactor
activity of factor Va. Cleavage at Arg506 occurs rapidly and results in an intermediate form
with a cofactor activity of approximately 60% compared with non-cleaved factor Va, whereas
cleavage at Arg306 occurs slowly and results in total inactivation of factor Va (66).
A naturally occurring mutation in the factor V gene causes a change in amino acid residue
506 from Arg to Gln (68-70). This mutation (factor VR506Q or factor VLeiden) causes the
affected factor Va molecule to become insensitive to inactivation by APC-mediated cleavage
at the 506 site, called APC resistance (71). In addition, factor V acts as a synergistic cofactor
with protein S in the APC-mediated inactivation of factor VIIIa (81-84), an anticoagulant
activity that is impaired in factor VR506Q (84,85). The presence of factor VR506Q is associated
with an increased risk for venous thrombosis that is caused by an impaired anticoagulant
pathway (72,73).
Factor Va is protected from APC-mediated cleavage at Arg506 by factor Xa, and this
protection is abolished by protein S (56,76). Protein S is a cofactor to APC, increasing the
affinity of APC for negatively charged phospholipids and specifically accelerating the APC-
mediated cleavage at Arg306 in factor Va (48-51). The acceleration of cleavage at the Arg306
site is accomplished by protein S-mediated topographical and/or conformational changes in
the active site of APC that localizes it closer to the membrane surface (64). Protein S cofactor
activity is regulated by C4b-binding protein (C4BP), an important regulator of the classical
pathway of complement activation (101-103). C4BP contains several identical a-chains and a
single b-chain. Binding of complement component C4b is mediated by the a-chains, whereas
protein S binds to the b-chain with high affinity resulting in a 1:1 stoichiometric complex
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(118,119). Binding of protein S to C4BP results in a decreased cofactor activity of protein S
to APC.
In this study we investigated the effect of C4BP n the APC-mediated inactivation of
factor Va on a phospholipid surface in both the absence and presence of protein S in a purified
system. A protein S-independent effect of C4BP on the APC-mediated inactivation of factor
Va is described.
Methods
Proteins
Human factor V was purified as described previously (221) and activated according to the
method of Hackeng et al. (201). Protein C, protein C activator purified from Agkistrodon
contortrix contortrix (ACC) and anti-ACC polyclonal antibody were kindly provided by Dr.
W. Kisiel (Department of Pathology, University of New Mexico, Albuquerque, NM, USA).
Protein C was activated by ACC after which ACC was removed using anti-ACC polyclonal
antibody as described previously (212). C4BP was immunopurified from human plasma as
described by Hessing et al. (160). The DNA encoding the a-chain of C4BP was amplified
from a human liver cDNA library by PCR using oligonucleotides C4BPaF (5'
CGCGGATCCACATCAGCGAAGCAGCAGGCC 3') and C4BPaR (5'
CGCGGATCCCAGCAAGACACCTTTTCCTCC 3'). After amplification, the PCR product
was cleaved with BamHI (underlined) and cloned in BamHI-cleaved pZem229R. The
expression vector pZem229R was kindly provided by Dr. E. R. Mulvihill (Zymogenetics Inc,
Seattle, WA, USA). The sequence and orientation of the amplified region was confirmed by
dideoxy sequencing. This construct (that lacked the C4BP b-chain) was designated rC4BPa.
Baby hamster kidney cells were transfected with rC4BPa as described previously (203).
Expression of rC4BPa was performed in conditioned medium (UltraCHOTM, BioWhittaker,
Verviers, Belgium) and harvested medium was stored at -20 oC until needed for further use.
Purification of rC4BPa was performed using an immobilized monoclonal antibody against
the a-chain of C4BP (8C11). The concentration of C4BP preparations were determined in an
ELISA using 8C11 as a capturing antibody and peroxidase-conjugated monoclonal antibody
9H10 directed against the a-chain of C4BP as a detecting antibody. C4BP preparations were
applied to 4-15% gradient SDS-PAGE under reducing and nonreducing conditions and
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visualized by silver staining or transferred to polyvinylidene difluoride membrane (Millipore
Corp., Bedford, MA) for standard Western blotting procedures using monoclonal antibody
2F12 directed against the a-chain of C4BP followed by a polyclonal peroxidase-conjugated
antibody against mouse antibodies (Dako, Glostrup, Denmark). Human prothrombin, protein
S and factor X were purified as described by Hackeng et l. (201). Factor X was activated
with immobilized Russell's Viper Venom according to the method of Bock et al. (222).
Monoclonal antibody CLB-PS13 directed against protein S was a generous gift from Dr. J. A.
van Mourik (Central Laboratory of the Netherlands Red Cross Blood Transfusion Services,
Amsterdam, The Netherlands). A truncated b- hain of C4BP fused to a modified tissue
plasminogen activator (SCR-1+2) was constructed as described previously (205).
Preparation of phospholipid vesicles
Phospholipid vesicles containing 20% phosphatidylserine, 40% phosphatidylcholine and
40% phosphatidylethanolamine were prepared as described by van Wijnen et al. (213).
Preincubation of C4BP, rC4BPa, anti-C4BP monoclonal antibodies 9F6 and 9H10,
anti-protein S monoclonal antibody CLB-PS13, protein S and APC
Preincubations of C4BP, rC4BPa, anti-C4BP monoclonal antibodies, CLB-PS13 and
protein S were performed for 30 minutes at 37 oC in Tris-buffered saline (TBS; 50 mM Tris-
HCl, pH 7.4, 150 mM NaCl) containing 0.3% (w/v) bovine serum albumin (BSA) and 3 mM
CaCl2. After preincubation, APC was added and incubated for 3 minutes at 37 oC.
Inactivation of factor Va by APC and determinaton of residual factor Va activity
Human factor Va (6 pM) was incubated with APC (20 pM) at 37 oC in TBS containing
0.3% BSA, 5 mM phospholipid vesicles and 3 mM CaCl2. After inactivation, 15 ml aliquots
were taken from the inactivation mixture and residual factor Va activity was immediately
determined from the rate of factors Va-Xa catalyzed prothrombin activation in 60 ml mix ures
containing 1.5 pM factor Va/Vi derived from the inactivation mixtures, purified factor Xa (5
nM) and prothrombin (500 nM) in TBS containing 0.3% BSA, 10 mM phospholipid vesicles
and 3 mM CaCl2. The rate of thrombin formation was proportional to the amount of factor
Va.
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Results
Expression and purification of rC4BPa
C4BP consisting of only a-chains (rC4BPa) was obtained by expression of the a-chain
cDNA in baby hamster kidney cells. Expression levels in the medium were detected by
ELISA and were 1-5 µg/ml after 3 days of culture. After immunoaffinity purification,
rC4BPa appeared on SDS-PAGE as a single band with the same molecular weight as the
doublet of purified plasma C4BP, corresponding to the isoform of C4BP containing six or
seven a-chains (Figure 1). Due to glycosylation of the subunits that comprise the C4BP
molecule, both rC4BPa and purified plasma C4BP appeared under reducing conditions as a
diffuse band of approximately 75 kDa corresponding to the a-chain of C4BP (Figure 1A).
Due to high glycosylation and low molecular weight of the b-chain, this subunit was not
visible in reduced purified plasma C4BP in Figure 1. Purified plasma C4BP and rC4BPa
were both visualized by Western blotting using monoclonal antibody 2F12 directed against
the a-chain of C4BP (Figure 1B). On Western blot, a faint band was visible in the nonreduced
C4BP preparations that appeared at a molecular weight of approximately 200 kDa (Figure
1B), but this band was not visible on the silver stained gel (Figure 1A). rC4BPa did not bind
to protein S due to the the absence of the protein S-binding b-chai  of C4BP (data not
shown).
Figure 1. SDS-PAGE of rC4BPa and purified plasma C4BP.
Purified C4BP preparations were applied to 4-15% gradient SDS-PAGE under
nonreducing (lanes 1 and  2) and reducing (lanes 4 and 5) conditions and visualized by
silver staining (A) or Western blotting using monoclonal antibody 2F12 directed against
the a-chain of C4BP (B). Lanes 1 and 4, rC4BPa; lanes 2 and 5, purified plasma C4BP;
lane 3, molecular weight markers (kDa). The arrow indicates the border between stacking
and running gel.
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APC-mediated inactivation of factor Va and protective effect of C4BP
To investigate the effect of C4BP on the APC-mediated inactivation of factor Va, the
residual factor Va activity after different time periods of inactivation by APC was monitored
using a purified system. Inactivation of factor Va by APC in the presence of a phospholipid
surface resulted in a decrease in factor Va activity of 50% (Figure 2A). Protein S (50 nM)
further decreased the factor Va activity to 20%. Protein S cofactor activity to APC was
inhibited by preincubation of protein S with C4BP, and factor Va activity was restored to a
maximum of approximately 94% by preincubation with 150 nM C4BP. Interestingly, C4BP
had a protective effect on factor Va activity in both the absence and presence of protein S.
Maximum protection of factor Va from APC-mediated inactivation was observed at 100 nM
C4BP in the absence of protein S and 150 nM in the presence of protein S. C4BP did not have
an effect on factor Va activity in the absence of APC.
Figure 2. APC-mediated inactivation of factor Va.
Factor Va (6 pM) was inactivated by APC (20 pM) in the presence of 5 mM phospholipid
vesicles at 37 oC for 4 minutes. Before inactivation, APC was preincubated with 0-200 nM
C4BP (A) or 0-250 nM rC4BPa (B) in the absence or presence of protein S (50 nM). After
inactivation, the residual factor Va activity was determined as described in the Methods
section. £, no APC; , APC alone; , APC + protein S. Values are displayed as means of
at least three separate experiments ± SD.
To investigate if the protective effect of C4BP was mediated by the a-chains, the same
experiments were performed with rC4BPa (Figure 2B). Like C4BP, rC4BPa also protected
factor Va from APC-mediated inactivation in the absence of protein S, and maximum
protection was observed at 100 nM rC4BPa. In the presence of protein S, rC4BPa inhibited
the factor Va inactivation to approximately 75% at 160 nM rC4BPa. The remainder of the
inactivation was most likely caused by the protein S cofactor activity to APC that could not be
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inhibited by rC4BPa. Again, rC4BPa did not have an effect on the factor Va activity in the
absence of APC.
The possibility that the C4BP-mediated effect was caused by a contamination of the used
purified components with trace amounts of protein S was excluded by performing the same
experiments using CLB-PS13, a monoclonal antibody directed against protein S that inhibits
the cofactor activity of protein S (Figure 3). The protein S cofactor activity was inhibited by
preincubation of protein S with 250 nM CLB-PS13, increasing the factor Va activity from
15% to 50%. Thus, CLB-PS13 inhibited the protein S cofactor activity but had no effect on
the inactivation of factor Va by APC in the absence of protein S. Addition of 250 nM CLB-
PS13 in the absence of protein S did not have an effect on the C4BP-mediated protection of
factor Va (data not shown).
Figure 3. Effect of a truncated C4BP b-chain (SCR-1+2) or CLB-PS13 on the protein
S cofactor activity in the APC-mediated inactivation of factor Va.
Factor Va (6 pM) was inactivated by APC (20 pM) in the presence of 5 mM phospholipid
vesicles at 37 oC for 4 minutes. Before inactivation, APC was preincubated with
increasing concentrations of SCR-1+2 (circles) or CLB-PS13 (squares) in the absence
(open symbols) or presence (closed symbols) of 50 nM protein S. After inactivation, the
residual factor Va activity was determined as described in the Methods section. Values
are displayed as means of at least two separate experiments.
Effect of a truncated C4BP b-chain (SCR-1+2) on the protein S cofactor activity in
the APC-mediated inactivation of factor Va
The same experiments as shown in Figure 2 were performed with a truncated C4BP b-
chain as described previously (205). This truncated b-chain consisted of the first two amino-
terminal short consensus repeats (SCRs) from the b-chain fused to a modified tissue
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plasminogen activator (SCR-1+2). As shown in Figure 3, SCR-1+2 inhibited the protein S
cofactor activity caused by complex formation between protein S and SCR-1+2 whereas in
the absence of protein S, SCR-1+2 did not inhibit the APC-mediated inactivation of factor Va.
These results show that the a-c ain of C4BP protected factor Va from inactivation (even in
the absence of protein S), whereas the truncated b-chain only inhibited the protein S cofactor
activity, without inhibiting the protein S-independent inactivation of factor Va.
Time course of APC-mediated inactivation of factor Va
A time-dependent inactivation of factor Va by APC is shown in Figure 4. Factor Va
activity was stable in the absence of APC during the time period investigated (0-12 minutes).
Similar to the results shown in Figure 2, factor Va activity was reduced by APC alone to 50%
after 4 minutes inactivation. Inactivation of factor Va was accelerated by the addition of 50
nM protein S, resulting in a residual factor Va activity of 20% after 4 minutes inactivation.
Factor Va was almost completely inactivated by APC in the presence of protein S after 12
minutes.
Figure 4. Time course of APC-mediated inactivation of factor Va.
Factor Va (6 pM) was inactivated by APC (20 pM) in the presence of 5 mM phospholipid
vesicles at 37 oC. Before inactivation, APC was preincubated without C4BP (circles), with
160 nM C4BP (squares) or 160 nM rC4BPa (triangles) in the absence (open symbols) or
presence (closed symbols) of protein S (50 nM). After inactivation, the residual factor Va
activity was determined as described in the Methods section. During the time period
investigated, factor Va activity was stable in the absence of APC (á). Values are displayed
as means of at least two separate experiments.
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Factor Va inactivation was inhibited by the addition of 160 nM C4BP in both the absence and
presence of protein S, resulting in a factor Va activity after 4 minutes of approximately 80%.
The same inhibition of inactivation was observed with 160 nM rC4BPa i  the absence of
protein S. In the presence of protein S, rC4BPa protected factor Va only partly, resulting in a
residual factor Va activity after 4 minutes of approximately 60%, in agreement with the
absence of the protein S-binding b-chain in rC4BPa and thus the inability of rC4BPa to
inhibit the protein S cofactor activity.
Inhibition of the C4BP-mediated protection of factor Va in the absence of protein S
The C4BP-mediated protection of factor Va from APC-mediated inactivation was inhibited
by preincubation of C4BP with monoclonal antibody 9F6 directed against the a-chain of
C4BP (Figure 5). After preincubation of 100 nM C4BP with 0-1500 nM 9F6, the factor Va
activity decreased from 80% in the absence of 9F6 (maximum protection by 100 nM C4BP)
to 50% in the presence of 1500 nM 9F6 (no protection).
Figure 5. Inhibition of the C4BP-mediated protection of factor Va in the absence of
protein S.
C4BP (100 nM) was preincubated with increasing concentrations of monoclonal antibody
9F6 (open circles) or 9H10 (closed circles) directed against the a-chain of C4BP.
Preincubations were added to APC (20 pM) and incubated for additional 3 minutes at 37
oC. C4BP/monoclonal antibody/APC preincubation mixtures were added to factor Va (6
pM) in the presence of 5 mM phospholipid vesicles, and factor Va was inactivated for 4
minutes at 37 oC. After inactivation, the residual factor Va activity was determined as
described in the Methods section. Values are displayed as means of two separate
experiments. The dotted line indicates the factor Va activity in the presence of APC
without C4BP (no protection).
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Strikingly, a 50% inhibition of the C4BP-mediated protection was observed at approximately
7-8 fold molar excess of 9F6 over C4BP, corresponding to the number of a-chains present in
C4BP. Another monoclonal antibody directed against the a-chain of C4BP (9H10) did not
affect the C4BP-mediated protection of factor Va.
Discussion
One of the mechanisms for down regulation of coagulation is the inactivation of factor Va
by activated protein C (APC). APC proteolytically inactivates coagulation factor Va (39-41)
by cleavage at Arg306 and Arg506 (65). Cleavage at Arg506 occurs rapidly, resulting in an
intermediate form with a cofactor activity of approximately 60% compared with non-cleaved
factor Va. Cleavage at Arg306 occurs slowly and results in total inactivation of factor Va.
Cleavage at Arg306 is specifically accelerated by protein S, a cofactor to APC (66). The
cofactor activity of protein S to APC is inhibited by binding of protein S to C4b-binding
protein (C4BP), a regulator of the classical pathway of complement activation (101-103). We
studied the effect of C4BP on the APC-mediated inactivation of factor Va on a phospholipid
surface in both the absence and presence of protein S in a purified system.
We observed that purified plasma C4BP inhibited the APC-mediated inactivation of factor
Va in both the absence and presence of protein S (Figures 2 and 4). C4BP in the absence of
APC did not affect the factor Va activity, nor did C4BP affect the prothrombinase assay that
was used to measure residual factor Va activity after inactivation (not shown). The possibility
that the C4BP-mediated effect was due to a contamination of trace amounts of protein S was
excluded using CLB-PS13, an antibody that inhibits the protein S cofactor activity (Figure 3).
CLB-PS13 inhibited as expected the protein S cofactor activity, whereas in the absence of
protein S, CLB-PS13 did not have any effect on the inactivation of factor Va by APC. In the
absence of protein S, CLB-PS13 had no effect on the C4BP-mediated protection of factor Va
from inactivation by APC (not shown). The C4BP-mediated protection against inactivation by
APC in the absence of protein S was specifically inhibited by a monoclonal antibody against
the a-chain of C4BP (9F6, Figure 5), whereas another monoclonal antibody against the a-
chain of C4BP (9H10) did not inhibit the C4BP-mediated protection of factor Va. Both
monoclonal antibodies did not affect the prothrombinase assay that was used to measure
factor Va activity. Both monoclonal antibodies detected purified plasma C4BP and rC4BPa
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in Western blotting (not shown). These results indicate that the C4BP-mediated protection of
factor Va was specific and exclude the possibility that the effect was due to an artefact or a
contamination with traces of protein S.
A recombinant C4BP that lacked the b-chain (rC4BPa) also inhibited the APC-mediated
inactivation of factor Va (Figure 2B). Like purified plasma C4BP, rC4BPa did not have an
effect on the factor Va activity in the absence of APC, and rC4BPa also did not affect the
prothrombinase assay that was used to measure the residual factor Va activity after
inactivation (not shown). In the presence of protein S, rC4BPa protected factor Va to a
maximum residual factor Va activity of approximately 75%. Since rC4BPa lacked the protein
S-binding b-chain, this was most likely caused by the fact that rC4BPa could not inhibit the
protein S cofactor activity, thus leading to a decreased level of factor Va protection compared
with purified plasma C4BP.
Although the inhibition of APC-mediated inactivation of factor Va by 160 nM purified
plasma C4BP (Figure 2A) or rC4BPa (Figure 2B) in the absence of protein S was almost
complete after 4 minutes incubation, the inactivation continued slowly upon further
incubation (Figure 4). The remainder of the inactivation may be due to cleavage at Arg306, a
cleavage that is known to take place at a slow rate (66). In th presence of protein S, 160 nM
purified plasma C4BP inhibited the protein S cofactor activity and in addition protected factor
Va to the same extent as in the absence of protein S. Since rC4BPa lacked the protein S-
binding b-chain, rC4BPa did not protect factor Va in the presence of protein S to the same
extent as purified plasma C4BP. Protein S increases the inactivation of factor Va by
specifically accelerating cleavage at Arg306 (66) and thus, the decreased protection by
rC4BPa compared with purified plasma C4BP may be caused by accelerated cleavage at
Arg306. Whether C4BP (from plasma and rC4BPa) protects a specific site in factor Va from
APC-mediated cleavage or if C4BP inhibits APC activity independent of the cleavage site by
sterical hindrance is presently not known.
Interestingly, a truncated form of the b-chain of C4BP as described previously (SCR-1+2,
205) inhibited the protein S cofactor activity whereas in the absence of protein S, SCR-1+2
did not affect the activity of factor Va (Figure 3). This confirmed that protection of factor Va
by C4BP was indeed mediated by the a-chains of C4BP, whereas the b-chain only inhibited
the cofactor activity of protein S. Since SCR-1+2 only contained the first two amino-terminal
short consensus repeat (SCR) modules (fused to a modified tissue plasminogen activator,
205), it was not a very potent inhibitor of the protein S cofactor activity. Although binding of
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protein S to APC is not inhibited by C4BP (103), steric hindrance may be involved in the
inhibition of protein S cofactor activity. SCR-1+2 is significantly smaller in size compared
with C4BP, and this may explain the weak inhibition of protein S cofactor activity by SCR-
1+2.
The inhibitory effect of C4BP on the APC-mediated inactivation was not found in a
previous study by Dahlbäck who used a similar system to measure the effect of C4BP in the
inactivation of factor Va (102). This discrepancy may be explained by the concentrations used
for APC and C4BP. In the system used by Dahlbäck, the APC concentrations were 10-50
times higher compared with our study. Since the C4BP concentrations used were similar in
the two studies, the APC concentrations used by Dahlbäck may have abrogated the C4BP-
mediated inhibition of factor Va inactivation. We used low concentrations of APC and factor
Va in order to mimic a physiological situation.
The finding that C4BP protected factor Va from APC-mediated inactivation may play a
role in the pathogenesis of thrombosis. C4BP is an acute phase reactant (116,117), and C4BP
concentrations can increase up to four-fold in an acute phase reaction. Increased C4BP levels
could result in an inhibition of factor Va inactivation, and may therefore explain the
thrombotic events that can occur during an acute phase response. The protection of factor Va
from APC-mediated inactivation in our purified system was observed at physiological
concentrations of C4BP, implying that factor Va inactivation would hardly occur in plasma.
However, in an APTT-based clotting assay using C4BP/protein S double deficient plasma as
described previously (205), addition of 200 nM C4BP did not affect the prolongation of
clotting time induced by 30 nM APC (not shown). Possibly, APC concentrations were too
high to result in a C4BP-mediated inhibition of inactivation or alternatively, C4BP-mediated
protection of factor Va is abrogated by a factor present in plasma.
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Chapter 6
General discussion
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The protein C anticoagulant pathway
The coagulation system is a cascade of proteolytic reactions that is necessary to stop
bleeding after tissue damage. Two important enzymatic complexes in coagulation are the
intrinsic factor X activating complex and the prothrombin activating complex. These
complexes are also called the intrinsic tenase and prothrombinase complex, respectively. In
the intrinsic tenase complex, factor VIIIa is a cofactor to the enzyme factor IXa that activates
the substrate factor X. Similar to the intrinsic tenase complex, factor Va is a cofactor to the
enzyme factor Xa that converts the substrate prothrombin into thrombin in the prothrombinase
complex. Thrombin is the final enzyme of the coagulation cascade that converts soluble
fibrinogen into fibrin. In this process fibrin monomers polymerize, ultimately resulting in the
deposition of an insoluble network of fibrin polymers. The coagulation cascade is necessary
to prevent blood loss upon vascular damage, but also requires tight regulation in order to
prevent thrombosis. An important step in regulation of coagulation is the inactivation of
coagulation factors Va and VIIIa by activated protein C (APC). APC proteolytically cleaves
these two activated cofactors resulting in inhibition of their cofactor activity. APC cleavage
sites within factor Va involve residues Arg306, Arg506 and Arg679 (65), and cleavage of the first
two sites correlate with loss of cofactor activity. Cleavage of factor Va at Arg506 occurs
rapidly and results in a factor Va molecule with an intermediate cofactor activity. Cleavage at
Arg306 occurs slowly and results in a total abrogation of cofactor activity (66). APC-mediated
inactivation of factor VIIIa cofactor activity involves a similar mechanism as described for
factor Va. APC cleavage sites within factor VIIIa involve residues Arg336, Arg562 and Arg740.
The first two cleavage sites are important in the APC-mediated degradation (78-80). Cleavage
of factor VIIIa at Arg562 occurs rapidly and correlates best with inactivation of factor VIIIa,
and cleavage at Arg336 occurs slowly.
In the inactivation of factors Va and VIIIa, protein S acts as a cofactor to APC. Protein S
increases the affinity of APC for the phospholipid surface and relocates the active site of APC
closer to the membrane surface (64). Relocation of the APC active site by protein S probably
localizes it closer to the Arg306 site of factor Va, thereby promoting a cleavage that results in
total inhibition of factor Va cofactor activity. Via this mechanism, protein S stimulates
inactivation of factor Va about 20-fold (67). A similar mechanism is most likely involved in
the APC-mediated inactivation of factor VIIIa. Protein S enhances cleavage at the Arg562 site
of factor VIIIa by APC (48,49,51), and in synergy with protein S, factor V further accelerates
this cleavage (81-84). In addition to its cofactor activity to APC, protein S also has an APC-
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independent anticoagulant activity. The APC-independent anticoagulant activity of protein S
involves direct inhibition of the intrinsic tenase and prothrombinase activity in vitro (52,53)
and requires direct interactions of protein S with phospholipids and coagulation factors VIIIa,
Xa and Va (54-58). The importance of protein C and protein S as inhibitors of coagulation is
demonstrated by the observation that a deficiency of these proteins is associated with
thrombosis (43-47,59-61).
The activity of protein S as a cofactor to APC in the inactivation of factors Va and VIIIa is
regulated via proteolytic inactivation by thrombin or other proteases (93,100). Thrombin-
cleaved protein S has no cofactor activity to APC, and has reduced calcium and phospholipid-
binding properties (94-97). The cofactor activity of protein S is also regulated by binding to
complement regulatory C4b-binding protein (C4BP, 101-103). C4BP is a complex multimeric
protein containing six or seven identical a-chains and a single b-chain (124-128). Each a-
chain contains a single binding site for C4b, and up to four molecules of C4b can be bound by
C4BP (144-148). The single b-chain that in normal conditions is present in 80% of all C4BP
molecules contains the protein S-binding site. Like many complement regulatory proteins, the
a- and b-chains are composed of short consensus repeats (SCRs), also called Sushi domains
or complement control protein (CCP) modules (149-152). The a-chain contains eight and the
b-chain contains three SCRs. The protein S-binding site has been localized on the first amino-
terminal SCR module (SCR-1) of the b-c ain, involving residues 34-42 (153-156). The
binding site for C4BP on protein S has been localized in the carboxy-terminal region of
protein S called the sex hormone binding globulin (SHBG)-like domain (166-168). In this
thesis, the protein S-C4BP interaction and the functional role of C4BP in the protein C
anticoagulant pathway was investigated.
Further localization of the protein S-binding site on the C4BP b-chain
In chapter two, it was investigated whether SCR-1 from the b-chain contains the entire
protein S-binding site or if other b-chain SCRs contribute to the interaction with protein S.
For this purpose, chimeras where constructed containing individual or adjacent SCRs derived
from the C4BP b-chain fused to the amino-terminus of a modified tissue plasminogen
activator (tPA) in which the active site serine residue was replaced by an alanine residue
(198). The tPA module of all the SCR-tPA chimeras contained Kringle domains I and II
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followed by the modified serine protease domain of human tPA. SCRs or combinations of
SCRs that were constructed are SCR-1, SCR-2, SCR-3, SCR-1+2, SCR-1+3 and SCR-2+3.
Strategies for the PCR amplification of the SCRs were based on the intron/exon organization
of the C4BP b-chain gene (202). A schematic representation of the construction of these SCR-
tPA chimeras is shown in Figure 1.
Figure 1. Schematic representation of the construction of SCR-tPA chimeras.
A) Short consensus repeats (SCRs) were amplified from the C4b-binding protein (C4BP)
b-chain. Forward (F) and backward (R) oligonucleotide primers that were used to amplify
the SCRs (1, 2 and 3) are indicated by arrows. Potential asparagine-linked glycosylation
sites are indicated by an asterisk (×). Dotted lines indicate intron/exon boundaries in the b-
chain gene. B) Example of a particular SCR-tPA chimera. At the carboxy-terminus, each
SCR or combination of SCRs is fused to a modified tissue plasminogen activator (tPA)
module that lacks the active site serine. The tPA module contains Kringle I, Kringle II and
a modified serine protease domain of tPA (indicated by a bar).
With direct binding assays and competition experiments it was shown that SCR-2
contributes to the interaction of protein S with SCR-1; the affinity of SCR-1+2 for protein S
being similar to plasma C4BP (2-5 nM). SCR-2 increased the affinity of the interaction
between SCR-1 and protein S approximately five-fold. In the chimera SCR-1+3, SCR-3 did
not contribute to the interaction of SCR-1 with protein S. In the chimera that only contained
SCR-1, SCR-1 was linked closer to the tPA module compared with the chimeras SCR-1+2
and SCR-1+3. However, the organization of the chimera SCR-1+2 was similar to SCR-1+3.
In both chimeras SCR-1+2 and SCR-1+3, SCR-1 was separated from the tPA module by a
single SCR. A minor difference between SCR-1+2 and SCR-1+3 was that the SCRs in SCR-
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1+2 were separated by four amino acid residues, whereas the SCRs in SCR-1+3 were
separated by three amino acid residues. However, the presence of three or four amino acid
residues between the SCRs is not a likely explanation for the difference found in the affinity
for protein S (see below). Since SCR-1+3 had the same binding affinity for protein S as SCR-
1, the contribution of SCR-2 in SCR-1+2 could not simply be ascribed to a sort of spacer
function of SCR-2. Instead, SCR-2 may induce conformational changes in SCR-1 that result
in a higher affinity interaction between SCR-1 and protein S. Alternatively, when SCR-2 is
adjacent to SCR-1 and SCR-1 is bound to protein S, SCR-2 may also bind to protein S,
thereby yielding a higher affinity binding of SCR-1+2 to protein S. Several regions within the
SHBG-loop of protein S have been hypothesized in the interaction of protein S with C4BP.
These regions include residues 408-434 (169-171), 447-460 (172), and 583-635 of protein S
(173-177, see Figure 6 in chapter one). It is tempting to speculate that SCR-1 and SCR-2 of
the b-chain each bind to one or more of these three putative binding sites.
The finding that SCR-2 contributes to the interaction between SCR-1 and protein S was not
in agreement with the studies performed by Härdig and Dahlbäck (156). In their study,
chimeras were constructed of C4BP a-chains with SCR-1, SCR-1+2 or SCR-1+2+3 replaced
by the corresponding SCRs derived from the b-chain. Thus, for example, the chimera with
SCR-1 of the a-chain replaced by SCR-1 of the b-c ain SCR-1 contained b-chain SCR-1
followed by the seven carboxy-terminal a-chain SCRs (SCR 2-8). At the carboxy-terminus,
each a-chain chimera contained a nonrepeat region with two cysteine residues. Like plasma
C4BP, six or seven of these modified a-chain subunits were thus incorporated into a single
molecule. All the a-chain chimeras had affinities for protein S comparable with plasma C4BP
(2-5 nM). From this it was concluded that SCR-1 contained the entire binding site for protein
S. To address the question if SCR-2 derived from the a-chain contributed in a similar manner
to the interaction with protein S like SCR-2 from the b-chain, a SCR-tPA chimera was
constructed that contained SCR-1 from the b-chain and SCR-2 from the a-chain (b1a2). The
affinity of this b1a2 SCR-tPA chimera for protein S was studied in chapter three using the
same binding studies as performed with the other SCR-tPA chimeras described in chapter
two. It was found that SCR-2 derived from the a-chain did not contribute to the interaction
with protein S, since b1a2 had the same affinity for protein S as SCR-1 and SCR-1+3. Like
SCR-1+2, the SCRs in b1a2 were separated by four amino acid residues (156), thus
confirming that the presence of three or four amino acid residues between the SCRs is not a
likely explanation for the difference in affinity for protein S. The discrepancy between our
87
study and the study with the a-c ain chimeras (156) may be explained by the fact that the a-
chain chimeras consisted of multiple (six or seven) subunits combined in a single C4BP
molecule (comparable with plasma C4BP). By combining multiple (six or seven) binding sites
for protein S in a single molecule, the effect of a lower binding affinity of each individual a-
chain chimera that had SCR-1 replaced by the b-chain counterpart may have been masked
(156).
Inhibition of the protein S cofactor activity
To investigate if the SCR-tPA chimeras like C4BP inhibited the protein S cofactor activity
to APC, an activated partial thromboplastin time (APTT)-based system was used.
Preincubation of protein S with the SCR-tPA chimeras that contained b-chain SCR-1 resulted
in an inhibition of protein S cofactor activity. In correlation with the affinity of each SCR-tPA
chimera for protein S, SCR-1+2 inhibited the protein S cofactor activity approximately five
times more potent than SCR-1, SCR-1+3 and b1a2. Interestingly, C4BP inhibited the protein
S cofactor activity approximately four times more potent than SCR-1+2 as measured with the
APTT-based system (Figure 4B in chapter four) whereas the affinity of SCR-1+2 for protein
S was comparable with C4BP (2-5 nM). In addition, it was found that SCR-1+2 had an effect
on the factor V and/or protein S-mediated effects in the APC-mediated inactivation of factors
VIIIa and Va that was several fold lower compared with C4BP (chapters four and five,
respectively). Plasma purified C4BP (and recombinant C4BP that only contained a-chains,
rC4BPa) protected factor Va against APC-mediated inactivation, an effect that was not found
for the SCR-tPA chimeras (chapter five). This may explain why C4BP was more potent in
inhibiting the protein S cofactor acivity compared with SCR-1+2. In addition, the C4BP
molecule is significantly larger than the SCR-tPA chimeras and thus, the more potent
inhibitory effect of C4BP compared with SCR-1+2 may also be explained by an increased
steric hindrance of C4BP compared with SCR-1+2. In that case, the -ch in c imeras as
described by Härdig and Dahlbäck (156) should inhibit the protein S cofactor activity
similarly to C4BP, since the a-chain chimeras had the same affinity for protein S and were
similar in size compared with C4BP. Unfortunately, the expression and purification of the a-
chain chimeras was not efficient enough, so this question could not be addressed (156).
Although steric hindrance may play a role in the inhibition of the cofactor activity of protein S
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to APC, binding of protein S to C4BP does not interfere with the binding of protein S to APC
(103). Hence, a ternary complex can be formed between protein S, C4BP and APC. The
mechanism by which the SCR-tPA chimeras inhibited the protein S cofactor activity is most
likely similar to C4BP. Protein S acts as a cofactor to APC by increasing the affinity of APC
for phospholipids and by relocating the active site closer to the membrane (64). R location
induced by protein S is most likely due to topographical and/or conformational changes, and
inhibition of the cofactor activity by C4BP or the SCR-tPA chimeras may be due to inhibition
of these topographical and/or conformational changes. Alternatively, binding of protein S to
C4BP or the SCR-tPA chimeras that contain b-ch i  SCR-1 may result in a conformational
change in protein S that prevents it from acting as a cofactor to APC.
The effect of binding of protein S to C4BP on the protein S cofactor activity to APC
in the inactivation of factor VIIIa
Until now, the effect of binding of protein S to C4BP on the protein S cofactor activity to
APC has only been studied in systems that monitor factor Va inactivation and in clotting
assays that measure the overall cofactor activity of protein S in plasma (84,101-103). In these
studies, it was shown that binding of protein S to C4BP resulted in an inhibition of cofactor
activity of protein S to APC. However, the effect of binding of protein S to C4BP on the
protein S cofactor activity to APC in the inactivation of factor VIIIa has, to our knowledge,
never been studied so far. In chapter four, we studied the effect of C4BP in the APC-mediated
inactivation of factor VIIIa using a purified system that measures factor VIIIa activity.
Interestingly, C4BP did not inhibit the protein S cofactor activity to APC in the inactivation of
factor VIIIa, whereas it inhibited the protein S cofactor activity in a similar system used to
monitor factor Va inactivation (chapter five). It is unclear why C4BP-bound protein S loses its
cofactor activity to APC in the factor Va inactivation (102, chapter five) but retains its
cofactor activity to APC in the factor VIIIa inactivation. In previous studies it was found that
protein S binds to factor VIII and that C4BP does not inhibit this interaction (54,190).
Possibly, the factor VIII bound C4BP-protein S complex retains its cofactor activity to APC
in the degradation of factor VIIIa. In synergy with protein S, factor V increases the
inactivation of factor VIIIa by APC (81,82). Once activated, factor V does not express this
synergistic cofactor activity (81,83,215,216). Factor V with the R506Q mutation (factor
VR506Q or factor VLeiden) that is resistant to APC cleavage at the 506 site, has a decreased
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anticoagulant activity compared with normal factor V (84,85). For factor V to act as an
anticoagulant cofactor, the C-terminal region of the factor V B-domain (215) and APC
cleavage at the Arg506 site (210,216) are required, although it is possible that conformational
changes occur in factor VR506Q that result in an impaired cofactor activity to APC. Protein
S/factor V synergistic cofactor activity involves binding of the two proteins (217,218) and
occurs via the SHBG loop of protein S (219). In contrast to the factor V-independent cofactor
activity of protein S to APC, the protein S/factor V synergistic cofactor activity was inhibited
by binding of protein S to C4BP. Most likely with the same mechanism as C4BP, the SCR-
tPA chimeras that contained b-chain SCR-1 also inhibited the protein S/factor V synergistic
effect in a dose-dependent manner that corresponded with their binding affinity for protein S.
In the inhibition of the protein S/factor V synergistic effect, C4BP was approximately three-
fold more potent compared with SCR-1+2, most likely due to increased steric hindrance of
C4BP compared with SCR-1+2. Binding of protein S to factors V and Va is inhibited by
C4BP (57) and this may contribute to the inhibition of protein S cofactor activity in the APC-
mediated inactivation of factor Va (102) and the protein S/factor V-mediated synergistic
inhibition of factor VIIIa activity (84, chapter four). The results described in chapter four and
previous findings indicate that the protein S/factor V-mediated inactivation of factor VIIIa
and the inactivation of factor Va play an important role in plasma and in contrast, the factor
V-independent protein S cofactor activity in the factor VIIIa inactivation does not seem to
play a role in plasma. In the factor VIIIa inactivation assay, C4BP did not inhibit the factor V-
independent protein S cofactor activity to APC whereas it completely inhibited the factor V-
dependent cofactor activity of protein S. In addition, C4BP completely inhibited the protein S
cofactor activity in an APTT-based clotting assay. Previous findings demonstrated that in
plasma, the protein S/factor V synergistic effect is important since protein S variants that
lacked the functional SHBG loop of protein S had a normal factor V-independent cofactor
activity in purified systems but a decreased cofactor activity in plasma that was shown to be
due to an impaired factor V-dependent anticoagulant activity (213,219). This is also indicated
by APTT-based APC resistance assays that are used to detect factor VR506Q. In these assays,
addition of APC to normal plasma results in prolongation of clotting time. In factor VR506Q
plasma however, the clotting time is only marginally affected by the addition of APC. Since
the factor V-independent inactivation of factor VIIIa is not affected by the factor VR506Q
mutation, one would expect the clotting time to be prolonged by the addition of APC. This
indicates that factor V-independent inactivation of factor VIIIa may not occur or is not
detected in APTT-based clotting assays.
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A protein S-independent effect of C4BP on the protein C anticoagulant pathway
In chapter five, the effect of C4BP in the APC-mediated inactivation of factor Va was
studied using a purified system that measures factor Va activity. It was found that even in the
absence of protein S, C4BP protects factor Va against APC-mediated inactivation. Factor Xa
also protects factor Va against APC, but protein S abolishes this protective effect by
specifically accelerating cleavage at the Arg306 site (56,76). The question remains whether
C4BP protects a specific site from cleavage by APC or if C4BP inhibits the activity of APC
independent of the cleavage site. For example, if C4BP specifically protects the 506 site from
APC-mediated cleavage (comparable with factor Xa), then this protection should be absent in
activated factor VR506Q. The effect of C4BP on the APC-mediated inactivation of factor
VR506Q is a subject for further study. In case C4BP specifically protects Arg506 from APC-
mediated cleavage, then factor Xa and C4BP may compete in the protection of factor Va
against inactivation by APC.
By the C4BP-mediated protection of factor Va, C4BP has a protein S-independent effect
on the anticoagulant activity of APC. A similar system to monitor factor Va inactivation was
used by Dahlbäck, who did not find this protective effect of C4BP on factor Va (102). The
discrepancy between the two studies may be explained by the concentrations of APC and
C4BP in the assays used. In the study by Dahlbäck, the concentration of APC used was 10-50
times higher compared with the study described in chapter five. Higher concentrations of
APC may prevent C4BP from protecting factor Va against inactivation. It is interesting to
note that in an APTT-based clotting assay, C4BP did not inhibit the prolongation of clotting
time by 30 nM APC in the absence of protein S. The relatively high concentration of APC
may have abrogated the C4BP-mediated protection of factor Va. Alternatively, the C4BP-
mediated inhibition of factor Va inactivation may be abrogated by another factor present in
plasma, and a possible candidate for this is factor Xa.
The observation that C4BP protects factor Va from APC-mediated inactivation as
described in chapter five may have consequences in situations where C4BP levels are
increased. C4BP is an acute phase reactant, and C4BP levels can increase up to four-fold
during inflammation, infection or tissue damage (116,117). In most cases, an increase in
C4BP levels involves mainly the C4BP isoforms that lack the b-chain, resulting in stable
levels of free protein S even during an acute phase reaction (130,131). By this mechanism of
differential regulation of C4BP a- and b-chain expression, increased C4BP levels will
normally not lead to an increased risk for thrombosis due to decreased anticoagulant protein S
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levels. If the protective effect of C4BP on factor Va against inactivation by APC takes place
in plasma however, increased C4BP levels may play a role in the pathogenesis of thrombosis.
The C4BP-mediated protection of factor Va yields an APC resistant factor Va phenotype
already at physiological C4BP levels, implying that factor Va inactivation would hardly occur
in plasma. However, the resulting increased procoagulant status is in that case counter
balanced by the APC-mediated inactivation of factor VIIIa, with protein S and factor V as
crucial synergistic cofactors. The cofactor activity of factor V in the inactivation of factor
VIIIa is impaired in factor VR506Q, causing an increased risk for venous thrombosis and
thereby indicating the importance of factor V as an anticoagulant factor.
C4BP: pro- or anticoagulant?
The primary function of C4BP in regulating coagulation is the binding of protein S.
Previous studies indicated that binding of protein S to C4BP resulted in an inhibition of the
cofactor activity of protein S to APC. For this reason, C4BP is supposed to have a
procoagulant effect. However, we found that C4BP did not inhibit the factor V-independent
protein S cofactor activity in the inactivation of factor VIIIa by APC and consequently, the
procoagulant effect of C4BP would be less pronounced than was previously assumed. The
factor V-independent inactivation of factor VIIIa however hardly occurs in plasma as
indicated by APTT-based APC resistance tests, whereas the protein S/factor V-mediated
enhancement of factor VIIIa inactivation is an important mechanism of down regulation of
coagulation. Since C4BP inhibited the factor V-dependent cofactor activity, the effect of
C4BP would be procoagulant.
By the protection of factor Va from APC-mediated inactivation as described in chapter
five, C4BP would again have a procoagulant effect. Since C4BP-mediated protection already
occurred at physiological levels, this would imply that inactivation of factor Va could not take
place in plasma. However, the C4BP-mediated protection of factor Va may be abrogated by
APC or another factor present in plasma. The effects of C4BP on the APC-mediated
inactivation of factors VIIIa and Va as described in this thesis are summarized in a schematic
presentation shown in Figure 2. In addition of procoagulant effects of C4BP, also an
anticoagulant effect of C4BP has been described in previous studies, involving the inhibition
of the intrinsic tenase activity in synergy with protein S in the absence of APC (190).
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C4BP is an acute phase reactant and during an acute phase reaction, increased C4BP levels
may account for the thrombotic events that can occur. Decreased levels of functional free
protein S would be a likely explanation. However, increased C4BP levels mainly occurs via
increase of C4BP isoforms that lack the b-chain, thereby in most cases resulting in stable
levels of free protein S. Via the protection of factor Va from APC-mediated inactivation
however, C4BP may play a role in the process of thrombosis.
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Figure 2. Schematic presentation of the effects of C4BP on the APC-mediated
inactivation of coagulation factors VIIIa and Va.
APC-mediated inactivations of factors VIIIa (A-C) and Va (D-E) are displayed in the
absence (left panel) or presence (right panel) of C4BP. Enhancement of APC-mediated
inactivation by protein S or protein S + factor V is indicated by an increased size of the
arrow plus an increased gap in the inactivated factor at the right of each panel. A+B: no
effect of C4BP; C-E: inhibitory effect of C4BP. The inhibitory effect of factor IXa on the
inactivation of factor VIIIa and the inhibitory effect of factor Xa on the inactivation of factor
Va is not displayed.
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Nederlandse samenvatting
Haemostase
Alle organen en weefsels van hogere organismen worden voorzien van voedingsstoffen en
zuurstof door middel van het bloedvatstelsel. Het bloedvatstelsel is een uitgebreid systeem
van vaten dat ervoor zorgt dat bloed naar alle organen en weefsels stroomt. Bloed bevat rode
bloedcellen, witte bloedcellen, bloedplaatjes en plasma. Rode bloedcellen zorgen voor het
transport van zuurstof van de longen naar de weefsels en van koolstofdioxide (een
afvalprodukt uit de weefsels) van de weefsels naar de longen. Witte bloedcellen zorgen voor
de afweer tegen micro-organismen. Plasma is de vloeistof waarin alle andere bestanddelen
zijn opgelost en bevat hormonen en talloze eiwitten. Aangezien bloed een belangrijke functie
heeft in de regulatie van lichaamstemperatuur, zuurstof voorziening van weefsels en het
functioneren van cellen, is het behoud van het bloedvatstelsel van cruciaal belang. Bij
verwonding treedt weefselschade op, en overtallig bloedverlies zou het gevolg zijn als er geen
natuurlijk mechanisme zou zijn om het bloeden te stoppen. Om bloedingen te voorkomen, zijn
er een aantal mechanismen die op gang komen bij weefselschade. Ten eerste trekken de
bloedvaten samen op de plaats van beschadiging, waardoor er al minder bloedverlies op kan
treden. Ten tweede hechten bloedplaatjes aan de vaatwand en vormen daarmee een
plaatjesprop. Ten derde wordt een netwerk van fibrinedraden gevormd die de plaatjesprop
verstevigt. De vorming van het fibrine netwerk wordt bloedstolling genoemd. Door
verschillende mogelijke oorzaken wordt de bloedstolling soms onnodig op gang gebracht. Als
gevolg daarvan vormt zich dan een bloedstolsel in een bloedvat waardoor het erachter
liggende weefsel onvoldoende voorzien wordt van bloed: trombose. Trombose kan leiden tot
weefselschade of zelfs weefselsterfte. Een verslechterde conditie van de bloedvaten of de
aanwezigheid van overgevoelige bloedplaatjes kan leiden tot de vorming van een plaatjesprop
doordat bloedplaatjes geactiveerd worden (bijvoorbeeld bij atherosclerose of aderverkalking).
Wanneer de activatie van bloedplaatjes en/of bloedstolling achterwege blijft terwijl het juist
wel nodig is, treden er bloedingen op. Hetzelfde is het geval als een bloedstolsel te snel wordt
afgebroken (fibrinolyse). Het is dus duidelijk dat de bloedstelping (haemostase) heel
nauwkeurig gereguleerd dient te worden. Er zijn vele stoornissen in de haemostase die tot
trombotische of bloedings complicaties kunnen leiden.
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Bloedstolling
De vorming van het fibrine netwerk wordt gereguleerd door een complex systeem van
eiwitten dat zich in het bloed bevindt: de stollingscascade. Bij activatie van de
stollingscascade treedt een reeks van elkaar versterkende reacties op hetgeen uiteindelijk leidt
tot de vorming van trombine. Trombine is het enzym dat onder andere het opgeloste
fibrinogeen omzet in onoplosbare fibrine draden. Deze fibrine draden vormen vervolgens het
fibrine netwerk waarin bloedplaatjes “gevangen” worden. Onder normale omstandigheden
wordt de stollingscascade pas geactiveerd wanneer er weefselschade optreedt. Bij
weefselschade is de vaatwand van een bloedvat (het endotheel) beschadigd waardoor het
bloed in contact komt met stoffen buiten de bloedbaan. Een van deze stoffen is tissue factor,
dat de stollingscascade activeert. Na activatie vindt het verder doorlopen van de
stollingscascade voornamelijk plaats op negatief geladen fosfolipiden oppervlakken. Negatief
geladen fosfolipiden (zoals fosfatidylserine) komen onder andere voor aan de buitenkant van
geactiveerde bloedplaatjes en op beschadigde cellen in de vaatwand. De stollingscascade is
schematisch weergegeven in figuur 1 van hoofdstuk 1.
Twee essentiële enzymreacties in de stollingscascade die plaatsvinden op negatief geladen
fosfolipiden zijn het intrinsieke tenase complex en het protrombinase complex. Het intrinsieke
tenase complex bevat het substraat factor X dat geactiveerd wordt door geactiveerd factor IX
(factor IXa). In deze enzymatische reactie zorgt geactiveerd factor VIII (factor VIIIa) voor
een versnelde omzetting: factor VIIIa is een cofactor voor factor IXa. Vergelijkbaar hiermee
bevat het protrombinase complex het substraat protrombine dat omgezet wordt in trombine
door geactiveerd factor X (factor Xa). In deze enzymatische reactie zorgt geactiveerd factor V
(factor Va) voor een versnelde omzetting: factor Va is een cofactor voor factor Xa. Door de
affiniteit van veel stollingsfactoren voor negatief geladen fosfolipiden brengt het negatief
geladen fosfolipiden oppervlak de stollingsfactoren dicht bij elkaar en versnelt daarmee de
stollingscascade. Het intrinsieke tenase complex en het protrombinase complex zijn
schematisch weergegeven in figuur 2 van hoofdstuk 1.
Het tijdens de stollingscascade gevormde trombine is verantwoordelijk voor de vorming
van het fibrine netwerk. Ook zorgt trombine voor de activatie van bloedplaatjes en van de
stollingsfactoren V en VIII. Door de activatie van de factoren V en VIII zorgt trombine voor
een versnelling van de vorming van zichzelf, via de verhoogde activiteit van het
protrombinase complex en van het intrinsieke tenase complex.
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Het proteïne C systeem
Een belangrijk mechanisme voor regulatie van de bloedstolling is het proteïne C systeem.
Lage concentraties trombine worden opgevangen door een receptor die aanwezig is op het
endotheel: trombomoduline. Wanneer trombine gebonden is aan trombomoduline kan het
proteïne C activeren. Geactiveerd proteïne C (APC) remt de stollingsfactoren Va en VIIIa op
een fosfolipiden oppervlak. De activatie van het proteïne C systeem is schematisch
weergegeven in figuur 3 van hoofdstuk 1. Door de activatie van proteïne C wordt de
procoagulante eigenschap (stimulering van bloedstolling) van trombine dus omgezet in een
anticoagulante eigenschap (remming van bloedstolling). Door de cofactor van het intrinsieke
tenase complex (factor VIIIa) en de cofactor van het protrombinase complex (factor Va) te
inactiveren, remt APC de stollingscascade. Mensen met een proteïne C deficiëntie hebben een
verhoogd risico op trombose, hetgeen het belang van het proteïne C systeem benadrukt.
De inactivatie van de stollingsfactoren Va en VIIIa gaat door middel van het proteolytisch
knippen van deze factoren door APC. In het factor Va molecuul zijn twee plaatsen aanwezig
die bij knippen door APC leiden tot inactivatie: na het aminozuur arginine op de 306 plaats
(Arg306) en na het aminozuur arginine op de 506 plaats (Arg506). De knip na Arg506 gaat snel
en leidt tot gedeeltelijke inactivatie van factor Va, de knip na Arg306 gaat langzaam en leidt tot
volledige inactivatie van factor Va. Ook in het factor VIIIa molecuul zijn twee plaatsen
aanwezig die bij knippen door APC leiden tot inactivatie: na het aminozuur arginine op de
336 plaats (Arg336) en na het aminozuur arginine op de 562 plaats (Arg562). De knip na Arg562
gaat snel en correleert het beste met de inactivatie van factor VIIIa, de knip na Arg336 gaat
langzaam.
Proteïne S
Wanneer de factoren Va en VIIIa deel uit maken van het protrombinase complex en van
het intrinsieke tenase complex, zijn ze beschermd tegen inactivatie door APC. In het
protrombinase complex wordt factor Va door factor Xa beschermd en in het intrinsieke tenase
complex wordt factor VIIIa door factor IXa beschermd. Deze bescherming wordt opgeheven
door de cofactor van APC: proteïne S. Proteïne S verhoogt de affiniteit van APC voor
fosfolipiden en veroorzaakt een verandering in het APC molecuul waardoor het efficiënter
kan knippen. Door de proteïne S geïnduceerde verandering in het APC molecuul gaat APC
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meer knippen na Arg306 in het factor Va molecuul. Dit resulteert in een volledige inactivatie
van factor Va en hierdoor wordt de trombinevorming geremd. Een vergelijkbaar mechanisme
is waarschijnlijk verantwoordelijk voor de cofactor activiteit van proteïne S voor APC in de
inactivatie van factor VIIIa. De inactivatie van factoren Va en VIIIa door APC is schematisch
weergegeven in figuur 4 van hoofdstuk 1.
In de inactivatie van factor VIIIa wordt de door proteïne S geïnduceerde verhoging van de
activiteit van APC nog eens extra versterkt door factor V. Factor V en proteïne S fungeren dus
als synergistische cofactoren voor APC in de inactivatie van factor VIIIa. Deze vrij recent
ontdekte anticoagulante functie van factor V is sterk verminderd in een natuurlijk
voorkomende variant van factor V. In deze variant genaamd factor VLeiden is het aminozuur
arginine op de 506 plaats (Arg506) vervangen door het aminozuur glutamine (Gln506). Volgens
de eenletterige aminozuurcode wordt factor VLeiden o k wel factor VR506Q genoemd. Naast een
sterk verminderde cofactor activiteit voor APC in de inactivatie van factor VIIIa heeft factor
VLeiden nog een andere negatieve bijkomstigheid. Door de vervanging van Arg506 i  Gln506 kan
APC niet meer knippen op deze plaats in het geactiveerde factor V molecuul. Het
geactiveerde factor V molecuul is dus ongevoelig geworden voor deze inactivatieknip hetgeen
ook wel APC resistentie wordt genoemd. Ten gevolge van de verslechterde cofactor activiteit
voor APC in de factor VIIIa inactivatie en door de APC resistentie hebben dragers van de
factor VR506Q mutatie een verhoogd risico op trombose.
C4b-bindingseiwit (C4BP)
De activiteit van proteïne S wordt geremd door binding van proteïne S aan C4b-
bindingseiwit (C4BP). C4BP is een regulator van het complement systeem, een cascade
systeem dat onder andere betrokken is bij de afweer tegen micro-organismen. Het C4BP
molecuul bestaat uit zes tot zeven identieke a-ke ens, en 80% van alle C4BP moleculen bevat
ook een enkele b-keten. Zowel de a-ketens als de b-keten zijn opgebouwd uit korte homologe
stukjes die veel voorkomen in complement regulatoire eiwitten: short consensus repeats
(SCRs). De a-ketens hebben elk acht SCRs, de b-ket n heeft drie SCRs. Het C4BP-molecuul
is schematisch weergegeven in figuur 5 van hoofdstuk 1. Proteïne S bindt aan de b-keten v n
C4BP, en de eerste (amino-terminale) SCR (SCR-1) is essentieel voor deze interactie.
In hoofdstuk 2 is beschreven dat de tweede (amino-terminale) SCR (SCR-2) de interactie
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van proteïne S met SCR-1 versterkt. Dit is onderzocht door de SCRs van de b-keten vast te
zetten aan tissue plasminogen activator (tPA chimeren). De constructie van deze tPA
chimeren is schematisch weergegeven in figuur 1 van hoofdstuk 6. Om de interactie tussen
proteïne S met SCR-1 te versterken moet SCR-2 aan SCR-1 vast zitten, want SCR-2 alleen
bindt niet aan proteïne S en ook los toegevoegd SCR-2 levert geen bijdrage aan de interactie
De eventuele bijdrage van andere SCRs is reeds eerder onderzocht door Härdig en
Dahlbäck. Dit is gedaan door een C4BP molecuul te construeren bestaande uit a-ke ens
waarvan respectievelijk SCR-1, SCR-1 en SCR-2 of SCR-1, SCR-2 en SCR-3 vervangen zijn
door de overeenkomstige SCRs van de b-keten. Härdig en Dahlbäck vonden op die manier dat
er geen bijdrage is van de overige SCRs in de interactie tussen proteïne S en SCR-1. Om uit te
zoeken of in de studie door Härdig en Dahlbäck de interactie van proteïne S met SCR-1
versterkt wordt door SCR-2 van de a-keten, is er in hoofdstuk 3 een tPA chimeer
geconstrueerd met SCR-1 van de b-ket n en SCR-2 van de a-keten. SCR-2 van de a-keten
levert geen bijdrage aan de interactie van proteïne S met SCR-1. De verklaring voor het
verschil met de studie door Härdig en Dahlbäck is mogelijk te vinden in het feit dat zij
meerdere (zes tot zeven) bindingsplaatsen hebben gecombineerd in een molecuul. Hierdoor is
het effect van de lagere affiniteit van de interactie tussen proteïne S en de a-k tens waarvan
SCR-1 vervangen is door SCR-1 van de b-ket n mogelijk gemaskeerd.
Remming van proteïne S cofactor activiteit
Vergelijkbaar met C4BP, wordt de cofactor activiteit van proteïne S voor APC geremd
door de tPA chimeren die SCR-1 van de b-ket n bevatten. Overeenkomstig met de hogere
affiniteit voor proteïne S, wordt de cofactor activiteit van proteïne S het sterkst geremd door
de tPA chimeer met daarin SCR-1 en SCR-2 van de b-keten (SCR-1+2). De cofactor activiteit
van proteïne S wordt minder effectief geremd door SCR-1+2 vergeleken met C4BP. Dit is
zowel in plasma het geval (hoofdstuk 2 en 3) als in de gezuiverde systemen die gebruikt zijn
om de inactivatie van factor VIIIa (hoofdstuk 4) en factor Va (hoofdstuk 5) te bestuderen.
Remming van de proteïne S cofactor activiteit gaat waarschijnlijk door middel van sterische
hindering. Aangezien de tPA chimeren aanzienlijk (ongeveer zeven keer) kleiner zijn dan
C4BP, vormt dit een mogelijke verklaring voor het verschil tussen SCR-1+2 en C4BP.
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In hoofdstuk 4 is de remming van de proteïne S cofactor activiteit voor APC in de
inactivatie van factor VIIIa door complexvorming met C4BP bestudeerd. Met behulp van
gezuiverde factoren is de inactivatie van factor VIIIa door APC bestudeerd in afwezigheid
van proteïne S, in aanwezigheid van proteïne S en in aanwezigheid van zowel proteïne S als
diens synergistische cofactor factor V. In tegenstelling tot wat tot nu toe werd aangenomen,
remt C4BP niet de proteïne S cofactor activiteit voor APC in de afwezigheid van factor V. De
factor V-onafhankelijke cofactor activiteit van proteïne S wordt dus niet geremd door C4BP.
Voor zover wij weten is dit de eerste keer dat het effect van C4BP op de proteïne S cofactor
activiteit in de inactivatie van factor VIIIa door APC in een gezuiverd systeem is bekeken. In
tegenstelling tot de factor V-onafhankelijke cofactor activiteit, wordt de factor V-afhankelijke
cofactor activiteit van proteïne S wel geremd door C4BP. Het synergistische effect van factor
V op de proteïne S geïnduceerde versnelling van de inactivatie van factor VIIIa door APC
wordt dus opgeheven door C4BP. Aangezien de cofactor activiteit van proteïne S in plasma
wel volledig wordt geremd door C4BP, betekent dit dat in plasma de factor V-onafhankelijke
inactivatie van factor VIIIa door APC nauwelijks plaats vindt. Het is echter ook mogelijk dat
de factor V-onafhankelijke inactivatie van factor VIIIa door APC niet of nauwelijks te meten
is in plasma.
In hoofdstuk 5 is de remming van de proteïne S cofactor activiteit voor APC in de
inactivatie van factor Va bestudeerd. Met behulp van gezuiverde factoren is de inactivatie van
factor Va door APC bestudeerd in zowel af- als aanwezigheid van proteïne S. Zoals eerder
beschreven remt C4BP de proteïne S cofactor activiteit voor APC in de inactivatie van factor
Va. Wij vonden echter dat in afwezigheid van proteïne S, C4BP een beschermende werking
heeft op factor Va tegen inactivatie door APC. De beschermende functie wordt uitgevoerd
door de a-ketens van het C4BP molecuul. Of C4BP een specifieke APC-gemedieerde knip in
het factor Va molecuul (na Arg306 of na Arg506) remt, zal in de toekomst verder worden
onderzocht. In plasma is deze bescherming van factor Va door C4BP geremd. Aangezien
factor Xa ook een beschermende werking heeft op factor Va tegen inactivatie door APC, is de
C4BP-gemedieerde bescherming in plasma mogelijk opgeheven door factor Xa of door een
ander eiwit in plasma.
De remming van de cofactor activiteit van proteïne S door C4BP en het beschermende
effect van C4BP op factor Va tegen inactivatie door APC zijn eigenschappen die C4BP een
procoagulant karakter geven. C4BP is een acuut fase eiwit hetgeen betekent dat het in
verhoogde concentraties in het bloed aanwezig kan zijn in situaties als ontsteking, infectie of
weefselschade. In de meeste gevallen betreft deze verhoging alleen de C4BP moleculen die
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geen b-keten bevatten, en zal de concentratie van vrij (actief) proteïne S dus normaal blijven.
Het beschermend effect van C4BP op factor Va tegen inactivatie door APC is echter
onafhankelijk van proteïne S en kan mogelijk een rol spelen bij de ontwikkeling van
trombotische complicaties wanneer C4BP concentraties sterk verhoogd zijn.
Inzicht in de mechanismen van de werking en de remming van het proteïne C systeem is niet
alleen van belang voor de behandeling van patiënten met trombotische complicaties maar ook
voor patiënten met septische shock. Bij septische shock veroorzaken bacteriën in het bloed
een levensbedreigende situatie. Het proteïne C systeem kan beschermend werken tegen de
complicaties die daarbij optreden. In dit proefschrift is het mechanisme van de interactie
tussen C4BP en proteïne S bestudeerd. Door meer inzicht te verkrijgen in het mechanisme van
deze interactie wordt het mogelijk om medicamenten te ontwikkelen die de interactie van
proteïne S met C4BP remmen en daardoor het proteïne C systeem beter laten functioneren.
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De schrijver van dit proefschrift werd geboren op 17 juni 1972 te Nijmegen. Na de lager
school “De Regenboog” in Malden volgde hij zijn middelbare schoolopleiding aan de
Nijmeegse Scholengemeenschap Groenewoud te Nijmegen. In juni 1990 haalde hij daar zijn
VWO diploma en in hetzelfde jaar begon hij zijn studie Biologie aan de Universiteit in
Utrecht. In juni 1995 haalde hij zijn doctoraalexamen met als specialisatierichtingen
Elektronenmicroscopische Structuuranalyse (onder begeleiding van Chris Schneijdenberg, Dr.
Jan Andries Post en Prof. Dr. Arie J. Verkleij, Faculteit Biologie, Universiteit Utrecht) en
Haematologie (onder begeleiding van Dr. Tom Vink en Prof. Dr. Jan J. Sixma, Faculteit
Geneeskunde, Universiteit Utrecht). In juli 1995 begon hij aan zijn onderzoek als assistent in
opleiding bij de Vakgroep Haematologie van de Faculteit Geneeskunde aan de Universiteit
Utrecht onder begeleiding van Prof. Dr. Bonno N. Bouma en Dr. Joost C. M. Meijers. De
resultaten van het onderzoek zijn beschreven in dit proefschrift.
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Dankwoord
Eindelijk is het dan zover. Als laatste geschreven maar meest l als eerste gelezen. Alle
mensen aan wie ik veel steun heb gehad en die mij geholpen hebben wil ik in dit stukje
behandelen.
Bonno, mijn promotor. Ik vraag me af of ik ooit nog zo’n relaxte begeleider zal krijgen als dat
jij voor mij bent geweest. Altijd kon ik bij je aankloppen als er iets was dat ik wilde vragen of
laten zien. Tijdens mijn bezoek aan Scripps bleek ook nog eens dat je een uitstekende
gastheer bent. Heel erg bedankt voor je begeleiding!
Joost, mijn co-promotor. Ook jij stond altijd klaar als er iets was. Nooit zal ik vergeten hoe je
altijd positief reageerde, zelfs op dingen die behoorlijk de mist in waren gegaan. Die aktie van
jou na “Lysis Analyzer” was echt klasse!
Dr. John Griffin. Thank you very much for giving me the opportunity to visit your lab!
During my stay I learnt a lot. I’ll never forget your advice that you gave to me when I left:
“Don’t bother if what you see is physiological or not, just seek the effect”. Thank you for all
the advice!
Björn Dahlbäck. It was an honour and a pleasure for me to work with you.
Sub (what’s up?!) or should I say Elvis? Thanks for the companionship and for helping me
out in San Diego. Keep the TPA alive and kicking, dude!
Wojciech: it’s a pitty that you couldn’t stay longer. We worked well together and had fun as
well. Thanks for writing down and translating Snap!
Collega’s van lab 2 (thuisbasis eerste hè), 3 en 1: bedankt voor alle gezelligheid, gekkigheid,
borrels, tips en truuks. D-D-D-Daan: bedankt voor je steun, echt kei top. Merel: bedankt voor
al jouw altijd even goede tips. Laurent (“Lazy” lerp) en Tony: keep the radio playing! Arnoud:
bedankt voor het proberen met de BIOcore, jammer dat de tijd te kort was. Total Tijtje (je liet
ons alleen…), G-G-G-Glenda: thanks for all the jokes, you always made me laugh. Winnie:
bedankt voor de aanzet tot “Lysis Analyzer”. Mark Roest: bedankt voor het bijspijkeren van
dat Turks-Duits tijdens die cursus Engels. Drink niet te veel bocht, beter is “oben unten, oben,
Elvira: bedankt voor het op peil houden van m’n Nijmeegs accent, kei gaaf. Hoie wâh!
Tom (gnè!), bedankt voor het bijbrengen van de fijne kneepjes van de moleculaire biologie
tijdens mijn stage en niet minder belangrijk: voor het slap geouwehoer! (Hoe gaat het nou?)
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Martin (meneer Philips), Rob (Robby), Marc (kappûh), Eric (zeg scheetje!), Livio en Douwe:
die “zinloze” video avonden moeten we blijven doen.
Chris en Jappie: het is inmiddels al weer lang geleden, maar ik ben jullie toch echt niet
vergeten: bedankt voor jullie begeleiding tijdens mijn eerste stage! Houdt die hartjes
kloppende…
Marlon ku Giovanni. Danki pa e tempo inolvidable na Aruba qual te ainda mi ta pensa ariba
dje. Apenas nos ta mira of papia ku otro, ma tog nos lo keda amigo.
Danny, Leonieke en Wendy: eindeloze studenten. Bedankt voor de gezelligheid op de
Warande. Ga die zieke beesten genezen!
Ivarski (Hehe): trouwe huisgenoot en vriend. Bedankt voor al je kennis en hulp op het gebied
van computers. Ik was niet altijd de gezelligste door zo laat thuis te komen. Nu weet je
waarom dat allemaal was.
Bas, biggest brother: bedankt dat jij mijn boekje vorm wilde geven. En of het vorm heeft
gekregen: het is echt harstikke mooi geworden! Han: b dankt dat ik m’n broer mocht lenen!
Erik, big bro: onverwoestbare rots technische kennis in de branding. Bedankt voor die
eindeloze avonden stappen.
Niels (Nikkel, Nielis): ik denk dat we elkaar nu zo’n twintig jaar kennen en al die tijd zijn we
beste maatjes gebleven. Vele serieuze gesprekken hebben we gehad maar ook ontzettend veel
lol (samen met de rest van Club Malden). Moatje, je bent mijn beste vriend.
Pa en ma: jullie hebben me altijd gesteund. Bedankt daarvoor en voor nog véél meer, ik hou
van jullie! Mam: die octopussen zijn gaaf geworden!
Laurien. Mijn lieve schattien. Als het allemaal even teveel werd wist jij me altijd gerust te
stellen. Als het goed ging, juigde jij met me mee en als het niet zo goed ging, baalde jij ook.
Jouw enthousiasme maakte en hield mij ook enthousiast. Dank je wel dat jij er voor me bent.
Ik heb je lief, ik hou van je!
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Translation of text on page 5:
The American firm of “Tranceptor Technology” started
the production of “Spoetnik” personal computers
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Dr. Tom Vink en Prof. Dr. Jan J. Sixma, Faculteit Geneeskunde, Universiteit Utrecht). In juli
1995 begon hij aan zijn onderzoek als assistent in opleiding bij de Vakgroep Haematologie van
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